A new role for NKG2D signaling in CD8+ T cells and autoimmune diabetes by Trembath, Andrew Peter
A new role for NKG2D signaling in CD8
+
 T cells and autoimmune diabetes 
By Andrew P Trembath 
  © 2019 
Submitted to the graduate degree program in Microbiology, Molecular Genetics and 
Immunology, and the Graduate Faculty of the University of Kansas in partial fulfillment of the 






Chair: Mary A. Markiewicz Ph.D 
 
 Wolfram R. Zückert Ph.D. 
 
Patrick E. Fields, Ph.D. 
 
Maria Kalamvoki Ph.D. 
 
Joe Lutkenhaus Ph.D 






The dissertation committee for Andrew Trembath certifies that this is the 
approved version of the following dissertation: 
A new role for NKG2D signaling in CD8
+





















The demands placed on the immune system are immense and highly complex. It must protect the 
body against untold threats while maintaining a balance between immune defense and 
autoimmune damage. One major player in immune recognition is the receptor Natural-Killer-
Group-2-Member-D (NKG2D), best known for its expression on natural killer (NK) cells and 
CD8
+
 T cells, where it recognizes NKG2D ligands expressed by stressed cells following viral 
infection or cancerous transformation. NKG2D is most well studied for its role in tumor 
immunity, for which NKG2D based therapies are currently being developed clinically. Despite 
this, it is apparent that NKG2D has other poorly understood immune regulating functions, such 
as its implicated involvement in type 1diabetes and other autoimmune disorders. However, the 
mechanism by which NKG2D signaling affects diabetes has been unclear. We therefore sought 
to further clarify the role NKG2D plays in autoimmune diabetes development. 
 
Canonically, NKG2D engaging NKG2D ligand results in immune killing of the infected or 
damaged ligand-bearing cell by NK cells, and costimulation of CD8
+
 cytotoxic lymphocytes 
(CTL) augmenting CTL responses and target cell killing. However, we and others have observed 
robust expression of NKG2D ligands by seemingly healthy immune cells. In the work presented 
in this dissertation, I show the work I performed to investigate how this expression by seemingly 
healthy cells affects the immune response. In particular I focused on CD8
+
 T cells, which express 
both NKG2D and NKG2D ligands after activation, and play a key role in the development of 




Using the non-obese diabetic (NOD) mouse model of autoimmune diabetes, I found that 
engagement of the NKG2D ligand H60a, expressed by NOD T cells, during CD8
+
 T cell 
differentiation resulted in decreased cytokine production upon later antigen stimulation. This 
correlated with other findings from our lab showing decreased incidence of autoimmune diabetes 
in microbiota-depleted NKG2D sufficient versus NKG2D deficient NOD mice. Further, I 
showed that this correlated with NKG2D signaling driving an increase in CD8
+
 T cells with a 
central memory phenotype in both mouse and human cells. I then found significantly reduced 
transfer of NOD diabetes by these central memory phenotype CD8
+
 T cells compared to 
effector/effector memory CD8
+
 T cells. NKG2D on human CD8
+
 T cells increases generation of 
a subset of CD8
+
 central memory phenotype T cells that match the surface phenotype of a 
described regulatory CD8
+
 T cell population. Finally, I found that NKG2D stimulation increased 
expression of the inhibitory receptor PD-1 by NOD CD8
+
 T cells. I therefore suggest a 
previously undescribed role for NKG2D signaling between healthy cells in immunity and 
immune regulation, and take steps towards answering critical questions to determine whether 
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Chapter 1: Introduction 
Parts of this chapter were previously published as an open access article (CC-BY) and are 
reprinted here with modification. Trembath AP and Markiewicz MA (2018) More than 
Decoration: Roles for Natural Killer Group 2 Member D Ligand Expression by Immune Cells. 
Front. Immunol. 9:231. doi: 10.3389/fimmu.2018.00231. 
 
The demands placed on the immune system are immense and highly complex. Tasked with 
protecting the body against untold external threats, while maintaining a balance between immune 
defense and autoimmune damage, the stakes are literally life and death. Fortunately, millions of 
years of evolution have resulted in immunological systems which are equally complex and 
necessarily efficient. Increasingly, we are coming to appreciate that few immune mechanisms are 
‘single use,’ with many systems having distinct functions dependent upon setting and context. 
While this immunological multi-purposing leads to a capable and nuanced immune response, it 
puts the onus on us to tease out the different roles played by many immune system components. 
A prime example is presented in the activating immune receptor Natural Killer Group 2 Member 
D (NKG2D) and its ligands. 
 
NKG2D, which is encoded by the gene Killer Cell Lectin Like Receptor K1 (Klrk1) and 
designated CD314, is one of the best-studied activating immune receptors. NKG2D is expressed 
by all human and mouse natural killer (NK) cells, all human CD8
+
 T cells, activated mouse 
CD8
+
 T cells, NKT cells, subsets of γδ T cells, and rare CD4
+
 T cells in both human and mouse 
(Bauer, Groh et al. 1999, Jamieson, Diefenbach et al. 2002, Groh, Bruhl et al. 2003, Dai, Turtle 
et al. 2009). The expression and general characteristics of NKG2D have been extensively 
2 
 
reviewed (Lanier 2015, Zhang, Basher et al. 2015, Wensveen, Jelencic et al. 2018, Zingoni, 
Molfetta et al. 2018). In brief, NKG2D is a C-type lectin-like receptor expressed on the cell 
surface as a disulfide linked homodimer with a short cytoplasmic tail that does not contain any 
signaling motifs. To signal, NKG2D associates with one of two adapter proteins, DNAX-
activating protein of 10 kDa (DAP10) or DNAX-activating protein of 12 kDa (DAP12). In 
human and mouse T cells and NK cells, NKG2D associates with DAP10, which has a YINM 
motif that induces PI3-kinase and Grb2-Vav signaling (Wu, Song et al. 1999, Lanier 2015). In 
mouse NK cells, NKG2D also associates with DAP12, which is an immunotyrosine-based 
activation motif (ITAM)-bearing signaling molecule that signals through Syk and Zap70 (Wu, 
Cherwinski et al. 2000, Gilfillan, Ho et al. 2002, Rosen, Araki et al. 2004) (Fig. 1). On NK cells, 
NKG2D is a primary activating receptor, triggering NK cell cytotoxicity and cytokine production 
in response to ligand-expressing cells. The function of NKG2D on CD8
+
 T cells is less well 
defined with both co-stimulatory and T cell receptor independent functions being described 
(Bauer, Groh et al. 1999, Meresse, Chen et al. 2004, Ehrlich, Ogasawara et al. 2005, Markiewicz, 





Figure 1: Schematic of NKG2D signaling in NK cells and CD8
+
 T cells. NKG2D is expressed 
as a homodimer which associates with intracellular adaptor proteins for signaling. In human NK 
cells, CD8
+
 T cells, and mouse CD8
+
 T cells, this adaptor is the YXXM motif containing protein 
DAP10 which subsequently signals through PI3-kinase Grb2-Vav1. Mouse NK cells express a 
shorter NKG2D isoforms which can also associate with the adaptor protein DAP12, which 
contains an ITAM motif, and signals through Zap70.  
 
NKG2D binds to a number of endogenous ligands (table 1) that are induced by cellular stress and 
were originally believed to be absent from healthy cells (Champsaur and Lanier 2010, Raulet, 
Gasser et al. 2013). There are 8 known human NKG2D ligands. These are MHC class I 
polypeptide-related sequence A (MICA) and B (MICB), and the Retinoic acid early transcript 1 
(RAET1) family of proteins, which are better known as the UL16-binding proteins (ULBP1-6).  
There are 9 known ligands for NKG2D in mouse. These are RAE1α-ε, H60a-c, and Murine 
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ULBP-like transcript 1 (Mult1), which are all orthologs of human RAET1. NKG2D ligands are 
all distantly related to MHC class I molecules, but do not associate with β2 microglobulin or 
bind peptide, and are tethered to the cell membrane via a GPI anchor or transmembrane domain 
(Lanier 2015). Specifically, MICA, MICB, ULBP4, H60a, H60b and MULT1 have 
transmembrane domains, while ULBP1, ULBP3, and ULBP6, Rae1α-ε and H60c, are attached to 
the cell surface via GPI anchors. Interestingly, ULBP2 and ULBP5 can be inserted into the 
membrane via a transmembrane domain or a GPI anchor (Lanier 2015). NKG2D ligands can be 
shed from the cell surface via proteolytic cleavage, alternative splicing, phosphoinositide 
phospholipase C, or exosome release (Chitadze, Bhat et al. 2013). While the ligands do have 
different binding affinities with NKG2D, all NKG2D ligands are believed to signal similarly 
through NKG2D (Champsaur and Lanier 2010, Raulet, Gasser et al. 2013). NKG2D ligands have 
generally been considered markers of ‘altered self,’ being induced by stress, such as cellular 
transformation or infection, and acting as a distress signal to target affected cells for immune 
killing. NKG2D ligands in host defense, as well as the mechanisms regulating ligand expression 
are the subject of a number of reviews (Raulet, Gasser et al. 2013, Lanier 2015, Zingoni, 
Molfetta et al. 2018). In addition to this well studied role directing immune killing of ligand-
expressing cells, a growing body of evidence suggests that NKG2D-NKG2D ligand interactions 
play other important roles in shaping the immune response. This idea came about after the 
appreciation of the importance of NKG2D ligand expression by otherwise healthy tissues (Eagle, 
Jafferji et al. 2009). Numerous reports show expression of NKG2D ligands by healthy tissues, 
but until relatively recently, the effects of this NKG2D ligand expression was not explored in 
depth. The expression of NKG2D ligands by healthy cells is the focus of a review by Eagle et al., 
wherein the authors address the potential significance of NKG2D ligand expression by both 
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healthy hematopoietic and non-hematopoietic cells and discuss the need for more systematic 
study of the role of NKG2D-NKG2D ligand signaling on apparently healthy cells (Eagle, Jafferji 
et al. 2009). In the years since this review, further evidence has accumulated that NKG2D ligand 
expression by healthy cells has distinct functions beyond targeting cells for immune killing. One 
major type of healthy cells, which evidence suggests routinely express NKG2D ligands, is cells 
of the hematopoietic lineage, specifically leukocytes. Many types of immune cells have been 
found to express NKG2D ligands with various immunological functions being reported, 
reviewed in Trembath and Markiewicz 2018 (Trembath and Markiewicz 2018)(Fig. 2). For my 
dissertation work, I focused on the expression of NKG2D ligands by T cells and the roles this 
expression plays in modulating the immune response by CD8
+
 T cells.  
 
Table 1: NKG2D ligands in humans and mice 
Human NKG2D Ligand Gene Name Membrane Tether 
MICA MICA Transmembrane 
MICB MICB Transmembrane 
ULBP1 RAET1I GPI anchor 
ULBP2 RAET1H GPI anchor/Transmembrane 
ULBP3 RAET1N GPI anchor 
ULBP4 RAETE Transmembrane 
ULBP5 RAET1G Transmembrane/GPI anchor 
ULBP6 RAET1L GPI anchor 
Mouse NKG2D Ligand Gene Name Membrane Tether 
H60a H60a Transmembrane 
6 
 
H60b H60b Transmembrane 
H60c H60c GPI anchor 
MULT1 Ulbp1 Transmembrane 
Rae1α Raet1a GPI anchor 
Rae1β Raet1b GPI anchor 
Rae1γ Raet1c GPI anchor 
Rae1δ Raet1d GPI anchor 
Rae1ε Raet1e GPI anchor 
 
 
In their 1998 paper first describing the human NKG2D ligand MICA, Zwirner and colleagues 




 T cells, but that 
expression could be strongly induced in culture by addition of the polyclonal T cell activator 
phytohemagglutinin (PHA) (Zwirner, Fernandez-Vina et al. 1998). Further investigation showed 
that MICA was induced on human T cells upon activation with anti-CD3 and anti-CD28 or PMA 
stimulation, and this induction could be inhibited in a dose dependent manner by the NF-κB 
inhibitor sulfasalazine (Molinero, Fuertes et al. 2004). In these studies, the authors suggest that 
MICA expression by T cells could participate in the maintenance of immune homeostasis 
through NKG2D-mediated NK cell killing  of  activated T cells (Molinero, Fuertes et al. 2002). 
Indeed, a number of studies in both human and mouse have since observed expression of 
NKG2D ligands by activated T cells, and found that this expression makes T cells susceptible to 
NKG2D-mediated killing. In mice, a study by Rabinovich et al. showed that upon activation, T 
cells from either C57BL/6 or Balb/c mice became susceptible to syngeneic killing by NK cells or 
lymphokine-activated killer cells (Rabinovich, Li et al. 2003). In Balb/c mice, this killing was 
7 
 
mediated by NKG2D and was due to upregulation of an NKG2D ligand, most likely H60a 
(Rabinovich, Li et al. 2003). Curiously however, no NKG2D ligands were detected on activated 
C57BL/6 T cells, suggesting that recognition and killing of activated syngeneic C57BL/6 T cells 
is mediated through a different receptor (Rabinovich, Li et al. 2003). In a model of graft-versus-
host disease, Noval Rivas and colleagues found that transferred host-specific CD4
+
 T cells were 
limited by NKG2D-dependent killing by host NK cells (Noval Rivas, Hazzan et al. 2010). They 
found that upon antigen stimulation, monoclonal antigen specific CD4
+
 T cells upregulated 
mRNA encoding the NKG2D ligands MULT1 and H60. It should be noted, however, that 
surface expression of MULT1 was not observed by flow cytometry, and surface expression of 
H60 proteins was not investigated (Noval Rivas, Hazzan et al. 2010). In humans, a similar 
finding was reported by Cerboni et al., who found that primarily MICA, but also ULBP1-3, were 




 T cells upon antigen stimulation in an ataxia 
telangiectasia mutated (ATM)/ataxia telangiectasia mutated- and Rad3-related protein (Molfetta, 
Quatrini et al.)-dependent manner. In addition, expression of these ligands by activated T cells 
resulted in NKG2D-mediated NK cell lysis, again suggesting a potential mechanism for limiting 
T cell responses (Cerboni, Zingoni et al. 2007). Nielsen et al. also found that activated CD4
+
 T 
cells expressed MICA, MICB, and ULBP1-3, and were susceptible to NK cell lysis (Nielsen, 
Odum et al. 2012).  Further evidence supporting this role comes from a recent study that showed 
expression of MICA and MICB by liver infiltrating T cells in patients with chronic hepatitis B 
correlated with enhanced NK cell activation and NKG2D-dependent depletion of CD4
+
 T cells 
upon short term ex vivo culture (Huang, Easom et al. 2017). It appears, however, that NKG2D- 
mediated T cell killing does not always result in a reduced immune response. For instance, 
during Mycobacterium tuberculosis infection, NK cells were shown to control regulatory T cell 
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(Treg) numbers through NKG2D-mediated lysis of NKG2D ligand-expressing Tregs (Roy, 
Barnes et al. 2008).  
 
As discussed above, multiple studies demonstrate that NKG2D ligand expression by human and 
murine T cells has an important function in regulating T cell responses by directing the 
elimination of activated T cells. However there is also evidence of additional functions for 
NKG2D ligands expressed on apparently healthy T cells. Li et al. found that NKG2D ligands 
were expressed by double positive Balb/c thymocytes prior to fate determination, suggesting a 
role for NKG2D ligand expression in thymocyte development (Li, Rabinovich et al. 2005). It 
was also shown that human PBMCs, and in particular CD4
+
 T cells, can release soluble NKG2D 
ligands in response to superantigen stimulation. These soluble ligands were found to 
downregulate NKG2D expression by CD8
+
 T cells, which showed impaired proliferation, 
cytokine production, and cytotoxic activity (Cerboni, Ardolino et al. 2009). Finally, emerging 
evidence suggests that expression of NKG2D ligands by T cells directly affects the production of 
cytokines. A recent article reported that expression of ULBP proteins by CD4
+
 T cells from 





 cells expressing NKG2D negatively correlated with inflammation 





Figure 2: Visual summary of immunostimulatory and immunosuppressive effects of 
natural killer group 2 member D (NKG2D) ligand expression by cells of the immune 
system. (A) The immunostimulatory effects of NKG2D ligand expression by immune cells. (1) 
NKG2D ligand expression by dendritic cells (DCs) and macrophages provides activating and 
differentiation signals to NKG2D-bearing natural killer (NK) cells and CD8
+
 T cells. (Granados, 
Draghi et al.) Expression of NKG2D ligand by regulatory T cells (Tregs) targets these cells for 
killing by NK cells, thereby increasing the overall immune response. (Campbell, Duggan et al.) 
NKG2D ligand expression may affect B cell cytokine production. (B) The immunosuppressive 
effects of NKG2D ligand expression by immune cells. (1) Widespread expression of NKG2D 
ligands by DCs or macrophages causes internalization of NKG2D, impairing NKG2D-mediated 
immune activation. (Granados, Draghi et al.) NKG2D ligand-bearing immune cells are directly 
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targeted for killing by autologous NKG2D-bearing NK and T cells. (Campbell, Duggan et al.) 
NKG2D–ligand interaction during CTL generation may decrease CTL cytokine production. For 
further review of NKG2D ligand expression by immune cell type, see Trembath and Markiewicz 
2018. 
 
Given that a major role of NKG2D and NKG2D ligands is directing the immune killing of 
infected or cancerous cells, it is logical to think that NKG2D may play a role in autoimmunity 
when this system aberrantly directs killing of healthy tissues. Indeed, NKG2D has been reported 
to be involved in a number of autoimmune conditions including multiple sclerosis (Fernandez-
Morera, Rodriguez-Rodero et al. 2008, Guerra, Pestal et al. 2013), colitis (Kjellev, Haase et al. 
2007), rheumatoid arthritis (Groh, Bruhl et al. 2003, Andersson, Sumariwalla et al. 2011), and 
autoimmune diabetes (Ogasawara, Hamerman et al. 2004, Qin, Lee et al. 2011, Van Belle, Ling 
et al. 2013, Trembath, Sharma et al. 2017), which is the focus of this dissertation. NKG2D is 
implicated to play a role in the development of autoimmune diabetes in both humans and mice. 
However reports describing what role NKG2D plays in disease development have been 
conflicting. An early report by Ogasawara and colleagues observed expression of the NKG2D 
ligand Rae-1 by cells of the pancreatic islets of NOD mice, and found that treatment with anti-
NKG2D blocking antibody prevented NOD diabetes development (Ogasawara, Hamerman et al. 
2004). Subsequent investigations, including our own , did not find Rae-1 mRNA (Angstetra, 
Graham et al. 2012, Carrero, Calderon et al. 2013) or Rae-1 protein expression in the NOD 
pancreas (Angstetra, Graham et al. 2012, Trembath, Sharma et al. 2017), and did not detect 
expression of NKG2D ligands on non-immune cells within the pancreatic islets of NOD mice 
(Trembath, Sharma et al. 2017). Using a RIP-LCMV model of diabetes, a study by Van Bell et 
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al. also concluded that antibody blockade of NKG2D had a beneficial effect, and reduced 
diabetes development in conjunction with antigen specific Treg therapy (Van Belle, Ling et al. 
2013). Contrary to these findings, a different study reported minimal effect of either NKG2D 
deficiency or anti-NKG2D antibody blockade on autoimmune diabetes development (Guerra, 
Pestal et al. 2013). In this dissertation, I describe a protective role for NKG2D signaling in NOD 
diabetes development (Trembath, Sharma et al. 2017). In this same study, work from the 
Markiewicz lab found that NKG2D signaling exerts opposing effects on NOD diabetes 
development in different anatomical locations (Trembath, Sharma et al. 2017), likely explaining 
the lack of consensus in previous studies. In humans, children with type I diabetes have been 
observed to have defects in NKG2D signaling (Qin, Lee et al. 2011), and decreased NKG2D 
expression by NK cells has been observed in those with type 1 diabetes (Rodacki, Svoren et al. 
2007). A genetic linkage study has also associated polymorphisms in the human NKG2D ligand 
MICA with diabetes susceptibility (Nikitina-Zake, Rajalingham et al. 2004). 
 
A major finding during my graduate work is that T cells from NOD mice express H60a upon 
activation. Because NOD CD8
+
 T cells also express NKG2D, I therefore set out to answer the 
question, how expression of NKG2D ligand by healthy T cells, affects CD8
+
 T cell response. I 
then further asked how this NKG2D signaling affects the development of autoimmune diabetes. 
This investigation led to the finding that interaction between NKG2D and H60a expressed by T 
cells during cytotoxic T lymphocyte (CTL) differentiation reduces NOD CTL effector cytokine 
production both in vitro and in vivo (Trembath, Sharma et al. 2017). I also investigated the 
effects of NKG2D-NKG2D ligand interactions between human CD8
+
 T cells, and found that this 
interaction also altered the CD8
+
 T cell response. I found that NKG2D signaling causes 
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increased generation of central memory phenotype (Tcm) CD8
+
 T cells and an increased ratio of 
Tcm to effector/effector memory phenotype (Teff+em) CD8
+
 T cell populations. Further, it is 
known that the CD8
+
 Tcm population contains a population of potent regulatory CD8
+
 T cells (Li, 
Xie et al. 2014) which I was able to observe. Finally, we show a significantly increased transfer 
of NOD diabetes by Teff+em versus Tcm CD8
+
 T cells. Together, these findings describe a new role 
for NKG2D signaling in CD8
+
 T cells whereby signaling during differentiation changes the 
resulting CD8
+







Chapter 2: A protective role for NKG2D-H60a interaction via homotypic T cell contact in 
NOD autoimmune diabetes pathogenesis 
 
This chapter was previously published as an open access article (CC-BY) excerpts of which are 
reprinted here in modified form. Trembath, A. P., N. Sharma, R. Saravanan, B. Polic and M. A. 
Markiewicz (2017). "A Protective Role for NKG2D-H60a Interaction via Homotypic T Cell 




The NKG2D immune receptor is implicated in both human and mouse autoimmune diabetes. 
However, the significance of NKG2D in diabetes pathogenesis has been unclear due to 
conflicting reports as to the importance of this receptor in the non-obese diabetic (NOD) mouse 
model. Findings from our lab demonstrate that NKG2D expression affects NOD diabetes 
development by at least two previously undescribed, and opposing mechanisms. I then show that 
the NKG2D ligand H60a is induced on activated NOD T cells, and that NKG2D-H60a 
interaction during CD8
+
 T cell differentiation into CTLs generally decreases the subsequent CTL 
effector cytokine response. This corresponds to data generated by others in the lab showing an 
increase in diabetes development in NKG2D-deficient compared with wild type NOD mice 
under microbiota-depleted conditions. Other lab members also demonstrated that NKG2D 
promotes NOD diabetes development through interaction with the microbiota. Together these 
findings reveal a previously undescribed role for NKG2D ligand expression by activated T cells 
14 
 
in CTL development, and demonstrate that NKG2D has both diabetogenic and antidiabetogenic 





In a previous study with the non-obese diabetic (NOD) mouse model, expression of RAE1 was 
observed in the pancreatic islets, and antibody blockade of NKG2D was found to inhibit CD8
+
 T 
cell infiltration and prevent diabetes development (Ogasawara, Hamerman et al. 2004).  It was 
subsequently shown that transgenic expression of RAE1ε by pancreatic β cells in non-
autoimmune C57BL/6 mice caused recruitment of activated CD8
+
 T cells to pancreatic islets 
(Markiewicz, Wise et al. 2012). This suggested a mechanism by which NKG2D ligand 
expression in the islets enhances diabetes development in NOD mice. However, RAE1 gene 
expression was not detected at any time during diabetes development in NOD pancreatic islets in 
two other studies (Angstetra, Graham et al. 2012, Carrero, Calderon et al. 2013). Additionally, 
diabetes development in NOD mice genetically deficient in NKG2D was reported to be similar 
to that of wild type NOD mice (Guerra, Pestal et al. 2013). These conflicting results suggest that 
NKG2D may play a more complex role in autoimmune diabetes development than originally 
proposed, affecting disease development through multiple mechanisms.   
 
Previous work in the Markiewicz lab compared diabetes development between Klrk1
-/-
 and wild 
type
 
NOD littermates housed under SPF conditions. They found that in both sexes, the Klrk1
-/-
 
mice exhibited slower diabetes development compared to wild type mice. Because NOD diabetes 
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is sensitive to alterations in the microbiota (Pozzilli, Signore et al. 1993, King and Sarvetnick 





NOD littermates treated with a broad spectrum antibiotic cocktail. In antibiotic 
treated animals, diabetes development was enhanced in Klrk1
-/-
 compared with wild type NOD 
mice. 
 
This pointed to at least two separate and opposing effects of NKG2D signaling, one resulting 
from interactions between NKG2D and the microbiota, and the other independent of microbiota 
interactions. My work presented here, investigates the effects of NKG2D signaling which is 
protective, and independent of microbiota interactions. Specifically, I focus on the role of 
NKG2D signaling on shaping the CD8
+
 T cell response.  
 
A previous report described the expression of RAE1 family members in the pancreatic β-islet 
cells of NOD mice and suggested that this expression targeted β-islet cells for autoimmune 
destruction (Ogasawara, Hamerman et al. 2004). Previous work from the Markiewicz lab looked 
for RAE1 mRNA expression in the pancreatic islets of our NOD mice, and did not detect RAE1 
mRNA in the pancreatic islets of wild type NOD mice in our colony (Trembath, Sharma et al. 
2017). Other lab members also looked for expression of the other NKG2D ligand expressed in 
NOD mice, H60a. These data showed significant expression of H60a mRNA in both the 
pancreas and spleen of NOD mice by 12 weeks of age (Trembath, Sharma et al. 2017). In 
addition, these data compared H60a mRNA levels between immune (CD45
+
) and non-immune 
(CD45
-
) cells present within isolated islets from 12 week-old mice and revealed H60a mRNA 
was expressed in the CD45
+
 immune cells, but not the CD45
-
 islet cells (Trembath, Sharma et al. 
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2017). Flow cytometry revealed that this expression was not on islet cells, but on infiltrating T 
cells. We further found that both H60a and NKG2D were expressed on NOD CD8
+
 T cells 
following activation, and that NKG2D-H60a interaction via homotypic CD8
+
 T cell contact 
during NOD CTL differentiation decreased effector cytokine production by the CTL in vitro. 
This corresponded with increased effector cytokine production by Klrk1
-/-
 NOD CTL in vivo and 
with previous data showing increased diabetes development in microbiota-depleted Klrk1
-/- 
NOD 
mice. These results demonstrate that NKG2D-ligand interaction during CTL generation dampens 








The NKG2D ligand H60a is expressed on infiltrating T cells within the pancreas of NOD mice  
Finally, I determined by flow cytometric analysis that the major cells expressing H60a were 




Figure 3: T Cells within the pancreas of NOD mice express the NKG2D ligand H60a A) 




 cells within the pancreas of a 12-week-old NOD mouse.  B) 




 T cells within the pancreas of a 12-week-old NOD mouse. 
The mean fluorescence intensity (MFI) of staining is shown. Data are representative of at least 






 T cells express NKG2D and H60a upon activation 
I next set out to determine the role of H60a expression by NOD T cells. I first characterized the 
expression of H60a on splenic T cells in young (6-8 week-old) NOD mice. I observed low, but 
detectable H60a expression on freshly isolated splenic T cells (Fig. 4). I tested whether activation 
would increase this expression by stimulating NOD splenocytes in vitro with anti-CD3 antibody. 




 T cells following activation, 
peaked on day 2 to 3 and remained elevated through day 5 of culture (Fig. 4).  
 
In addition to H60a, activated NOD CD8
+
 T cells express NKG2D (Ogasawara, Hamerman et al. 
2004). Therefore, I determined the time course of both H60a and NKG2D expression after initial 
TCR activation and differentiation of NOD CD8
+
 T cells into CTL. I purified CD8
+
 T cells from 
the spleens and lymph nodes of 6-8 week old Klrk1
-/-
 and wild type NOD mice. NKG2D and 
H60a expression was assessed at the time of cell isolation and daily following activation with 
anti-CD3 and anti-CD28 antibodies. Similar to what I observed with whole splenocytes (Fig. 5), 
a low level of H60a was detected prior to activation, this expression peaked 3 days after 
activation, and continued through day 5 (Fig. 5). This expression was unaffected by Klrk1 (Fig. 
5). In wild type mice, NKG2D became detectable at a low level on day 2, peaked at day 3, and 













cells following activation of NOD splenocytes with anti-CD3ε antibody. The MFI of staining is 




 gated live cells. Data are 








Figure 5: NOD CD8
+
 T cells express both H60a and NKG2D upon activation. Expression of 
(A) H60a and (B) NKG2D on CD8
+
 T cells purified from 6-8 week-old Klrk1
-/- 
and wild type 
NOD mice activated with anti-CD3ε and anti-CD28 antibodies.  MFI of staining is shown. Data 
are representative of at least 4 independent experiments. 
 
NKG2D expression alters NOD CTL effector cytokine responses in vitro and in vivo.  
NKG2D engagement by ligands expressed on target cells enhances CTL effector function 
induced by T cell receptor engagement by antigen expressed on the same target cells (Bauer, 
Groh et al. 1999, Markiewicz, Carayannopoulos et al. 2005). Given my finding that NOD CTL 
co-express NKG2D and the NKG2D ligand H60a, I hypothesized NKG2D-H60a interaction via 
homotypic CD8
+
 T cell contact could similarly alter NOD CTL effector function. To test this, I 
activated purified Klrk1
-/- 
and wild type NOD CD8
+
 T cells with anti-CD3 and anti-CD28 
antibodies in vitro and allowed them to differentiate for 5 days. I assessed cytokine production 
and lytic granule release by the CTL after re-stimulation with various concentrations of plate 
bound anti-CD3 antibody to mimic target cell recognition.  
 
In the absence of stimulation, or with a low concentration of anti-CD3 antibody, Klrk1
-/-
 CTL 
produced significantly more IFN, TNF, and IL-10 compared with wild type CTL (Fig. 6 and 
7A). With a higher concentration of anti-CD3 antibody, Klrk1
-/- 
CTL also produced greater 
amounts of TNF and IL-10. At this higher level of stimulation, IFN production by Klrk1
-/- 
CTL was lower in some experiments compared with
 
wild type CTL, however this did not reach 
statistical significance when data from multiple experiments were combined. (Fig. 6 and 7A). In 
contrast to this effect on cytokine production, no change in lytic granule release was observed 
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(Fig. 7B). To determine if NKG2D expression similarly affected NOD CD8
+
 T cell cytokine 
production in vivo, I purified CD8
+
 T cells from Klrk1
-/-
 or wild type NOD mice, and labeled 
them with eFluor 670 or CFSE, respectively. Without providing exogenous TCR activation, I 
adoptively transferred a 1:1 mixture of these cells into wild type NOD recipient mice (Fig. 8A). 
After 1 week, Klrk1
-/-
 cells recovered from the spleen produced more TNFα and IFNγ than wild 
type cells recovered from the same spleen (Fig. 8B and C). Together, these results demonstrate 
that that expression of NKG2D by NOD CD8
+
 T cells generally reduces effector cytokine 






Figure 6: Altered cytokine production by Klrk1
-/- 
NOD CTL in vitro. Secretion of TNFα, 
IFNγ, and IL-10 (mean+/-STD) by in vitro generated Klrk1
-/-
 and wild type CTL stimulated with 
the indicated concentrations of anti-CD3ε antibody. Data are representative of at least 6 









Figure 7: NKG2D deficiency alters NOD CTL cytokine production but does not 
significantly alter lytic granule release. (A) Fold change (mean +/- SEM) in TNF IFNγand 
IL-10secretion by Klrk1
-/-
 CTL compared with wild type CTL. Data are combined from at least 





 CTL compared with percent of CD107a+ wild type CTL. Data are combined 






Figure 8: Altered cytokine production by Klrk1
-/- 
NOD CTL in vivo. (A) Schematic of 
adoptive transfer and intracellular cytokine staining of labeled CD8
+
 T cells from wild type and 
Klrk1
-/-
 mice. (B) Representative flow cytometry plots showing intracellular staining of TNFα 
and IFNγ in Klrk1
-/-
 and wild type NOD CD8
+
 T cells 1 week after co-transfer into a wild type 
NOD adoptive transfer recipient mouse. (C) Combined results (mean+/-SEM) from transfers into 
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8 mice from three independent experiments showing the percent TNFα or IFNγ positive Klrk1
-/-
 
and wild type NOD CD8
+
 T cells 1 week after co-transfer into wild type NOD adoptive transfer 
recipient mice. **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 in two-tailed unpaired Mann-Whitney test. 
 
NKG2D-H60a interaction during NOD CTL differentiation dampens diabetogenic cytokine 
production. 
To assess whether the increased cytokine production by Klrk1
-/-
 CTL was the result of a loss of 
NKG2D interaction with H60a during the effector response, I included a blocking antibody 
against H60a during CTL stimulation. However, this blockade did not affect cytokine secretion 
by any of the CTLs (Fig. 9). This led us to hypothesize that NKG2D-H60a interaction during 
CTL differentiation, rather than during the effector CTL response, was responsible for the altered 
cytokine production by Klrk1
-/-
 CTL. To test this, we added anti-H60a blocking antibody at the 
beginning of the T cell culture. This resulted in increased TNFα, IL-10, and IFN by wild type 
CTL when the cells were stimulated with a low concentration of anti-CD3 antibody (Fig. 10 and 
11). With a higher concentration of anti-CD3 antibody, H60a blockade also resulted in greater 
production of TNFα and IL-10, but lower or similar production of IFNγ, by wild type CTLs (Fig. 
10 and 11). Confirming this effect of H60a blockade was dependent on NKG2D expression, no 
difference in cytokine production was observed between CD3-stimulated anti-H60a- and isotype 
control- treated Klrk1
-/-








Figure 9: CTL effector cytokine production is not affected by blockade of NKG2D-H60a 
interaction during NOD CTL effector response. (A) Representative experiment showing 
TNFα, IFNγ and IL-10 secretion (mean +/- STD) by Klrk1-/- and wild type CTL stimulated with 
anti-CD3ε in the presence of an anti-H60a or isotype control antibody. Data are representative of 
at least 4 independent experiments. *p ≤ 0.05 in one-tailed unpaired Mann-Whitney test. (B) 
Fold change (mean +/- SEM) in TNFα, IFNγ and IL-10 secretion by CTL stimulated with anti- 
CD3ε in the presence of anti-H60a compared with isotype control antibody. Data are combined 







Figure 10: Blockade of NKG2D-H60a interaction during NOD CTL differentiation results 
in increased CTL effector cytokine production. Secretion of TNFα, IFNγ, and IL-10 by in 
vitro generated Klrk1
-/-
 and wild type CTL stimulated with the indicated concentrations of anti-
CD3ε antibody in the presence of an anti-H60a or isotype control antibody. Data are 
representative of at least 6 independent experiments. *p ≤ 0.05, ***p ≤ .001, ****p ≤ .0001 in 




The similar effect of NKG2D deficiency (Fig. 6) and H60a blockade during CTL differentiation 
(Fig. 10 and 11) demonstrates that NKG2D-H60a interaction via homotypic CD8
+
 T cell contact 




Figure 11: Figure S4. Blockade of NKG2D-H60a interaction during NOD CTL 
differentiation increases CTL effector cytokine production.  Fold change (mean+/-SEM) in 
TNF, IFNγ and IL-10 secretion by Klrk1
-/-
 and wild type CTL stimulated with anti-CD3 
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generated in the presence of an H60a blocking compared with isotype control antibody.Data are 
combined from at least 6 independent experiments. *p ≤ 0.05 in one-tailed Wilcoxon test. 
 
 
Different pancreatic and splenic immune cell populations in specific pathogen free (SPF)-housed 
NOD mice vs. NOD mice treated with broad-spectrum antibiotics.  
 
Expression of TNFα, IFNγ and IL-10 within the islets all enhance NOD insulitis and diabetes 
development (Rabinovitch 1998). Given the increased production of these cytokines by Klrk1
-/- 
CTL, and the protective role of NKG2D in microbiota-depleted mice in NOD diabetes 
development, we hypothesized that increased cytokine production by CD8
+
 T cells in Klrk1
-/-
 
mice may contribute to the increased incidence of diabetes. We therefore sought to determine the 
immune cell populations present in the spleen and pancreas of wild type and Klrk1
-/-
 mice under 
both SPF and antibiotic-treated conditions. Antibiotic treatment did not significantly change 
expression of H60a (Fig. 12F and 13F) or NKG2D (Fig. 12G and 13G), and there was no 
difference in CD69 expression on immune cells in the pancreas or spleen between wild type and 
Klrk1
-/-
 mice under either condition (Fig. 12E and 13E). Antibiotic treatment did result in a 
decrease in CD4
+
 T cells in both the pancreas and spleen, and altered the ratio of effector to 
central memory CD4
+
 T cells in the pancreas (Fig. 12B, 12C, 13B and 13C).  Specifically, with 
antibiotics there were fewer effector CD4
+




) and more central memory 
CD4
+




) in the pancreas in both wild type and Klrk1
-/- 
mice (Fig. 13C). 
There was a similar increase in central memory CD8
+
 T cells in the pancreas; however, unlike 
the CD4
+
 T cell population, there was not a corresponding decrease in effector CD8
+
 T cells 
(Fig. 13D).  These data demonstrate that there were fewer effector T cells in the pancreas of the 
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antibiotic-treated mice. This corresponds with the reduced diabetes development in these mice 
compared with SPF-housed wild type mice, as well as the increased ability to observe the 







Figure 12: Immune cell populations, activation, and NKG2D and H60a expression in the 
spleen of untreated and antibiotic-treated Klrk1+/+ and Klrk12/2 NOD mice. (A) 
Percentage of total splenocytes in 12 wk old wild-type and Klrk12/2 NOD mice with or without 
antibiotic that were CD32 CD49b+ (NK cells), CD32 CD49b2 (non-T or NK cells), or CD3+ (T 
cells). (B) Percentage of splenic T cells in (A) that were CD4+ and CD8+. (C) CD62L and CD44 
expression by splenic CD4+ T cells in (A). (D) CD62L and CD44 expression by splenic CD8+ T 
cells in (A). (E–G) Percentage of splenic populations in (A) and (B) that expressed (E) CD69, (F) 
H60a, or (G) NKG2D. Data are combined results (mean 6 SEM) of at least four mice per group. 








Figure 13: Immune cell populations, activation, and NKG2D and H60a expression in the 
pancreata of untreated and antibiotic-treated Klrk1+/+ and Klrk12/2 NOD mice. (A) 
Percentage of cells isolated from the pancreata of 12 wk old wild-type and Klrk12/2 NOD mice 
with or without antibiotic that were CD32 CD49b+ (NK cells), CD32 CD49b2 (non-T or NK 
cells), or CD3+ (T cells). (B) Percentage of T cells in (A) that were CD4+ and CD8+. (C) 
CD62L and CD44 expression by CD4+ T cells in (A). (D) CD62L and CD44 expression by 
CD8+ T cells in (A). (E–G) Percentage of populations in (A) and (B) that expressed (E) CD69, 
(F) H60a, or (G) NKG2D. Data are combined results (mean 6 SEM) of at least four mice per 
group. *p # 0.05, **p # 0.01 in two-tailed unpaired Mann–Whitney U test. 
 
Discussion 
I demonstrated that interaction between NKG2D and H60a, both expressed on differentiating 
CTL, reduces the production of effector cytokines by NOD CTL. This corresponds with 
decreased diabetes development in antibiotic-treated Klrk1
-/-
 NOD mice.  
 
NKG2D is implicated in the development of autoimmune diabetes in both humans and mice 
(Ogasawara, Hamerman et al. 2004, Gambelunghe, Brozzetti et al. 2007, Markiewicz, Wise et al. 
2012, Van Belle, Ling et al. 2013), however a definitive role for NKG2D in this disease has not 
been established. Much of this uncertainty has been due to seemingly conflicting results in the 
NOD mouse model. Previous reports have demonstrated that NKG2D either promotes NOD 
diabetes (Ogasawara, Hamerman et al. 2004) or has little effect (Guerra, Pestal et al. 2013). In 
particular, Ogasawara et. al. (Ogasawara, Hamerman et al. 2004) suggested that expression of the 
NKG2D ligand RAE1 in pancreatic islets targets islet β cells for NKG2D-mediated destruction. 
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Dr. Markiewicz’s later finding that transgenic expression of RAE1 by islet β cells drove immune 
cell infiltration of pancreatic islets in the non-autoimmune C57BL/6 background seemed to 
support the feasibility of this model (Markiewicz, Wise et al. 2012). However, the Markiewicz 
lab did not detect expression of RAE1 mRNA, or any other NKG2D ligand, by CD45
- 
cells in 
pancreatic islets. This finding is consistent with other reports that found no RAE1 mRNA 
(Angstetra, Graham et al. 2012, Carrero, Calderon et al. 2013), or protein (Angstetra, Graham et 
al. 2012) expressed by NOD islet cells. These differing reports of RAE1 expression may be a 
result of variance between NOD mouse colonies due to gut microbial influence or genetic drift 
(Pozzilli, Signore et al. 1993, Yurkovetskiy, Burrows et al. 2013, Simecek, Churchill et al. 
2015). A report by Adlercreutz et. al. (Adlercreutz, Weile et al. 2014) did show expression of 
H60a mRNA in the pancreatic islets of 13 week old NOD and Balb/c mice, but did not 
distinguish between immune and non-immune cells. This is consistent with the H60a mRNA 
expression observed in the Markiewicz lab. 
 
My observation of robust H60a expression by activated NOD CD8
+
 T cells was not anticipated, 
but is consistent with earlier reports. H60a mRNA was previously shown to be expressed in 
healthy NOD tissues and by NOD NK cells (Ogasawara, Hamerman et al. 2003, Adlercreutz, 
Weile et al. 2014). Similar to the NOD mouse, Balb/c immune cells express H60a (Cerwenka, 
Bakker et al. 2000, Ogasawara and Lanier 2005, Takada, Yoshida et al. 2008), and mRNA 
encoding this NKG2D ligand was shown to be upregulated in Balb/c T cells upon activation 
(Rabinovich, Li et al. 2003). Likewise, human T cells also express NKG2D ligands upon 
activation (Zwirner, Fernandez-Vina et al. 1998, Molinero, Fuertes et al. 2002, Cerboni, Zingoni 




Constitutive NKG2D ligand expression decreases NKG2D surface expression on NK and CD8
+
 
T cells (Coudert, Zimmer et al. 2005, Wiemann, Mittrucker et al. 2005, Champsaur and Lanier 
2010). Poor NKG2D expression has been previously reported on NOD NK cells (Ogasawara, 
Hamerman et al. 2003), which correlated with RAE1 expression by these cells (Ogasawara, 
Hamerman et al. 2003). Similarly, the high level of H60a expression on NOD CD8
+
 T cells is 
likely responsible for the low surface expression of NKG2D we observed on these cells. 
However, our results clearly show that this low NKG2D expression has functional relevance to 
CTL differentiation. 
 
To date, the function of NKG2D in CD8
+
 T cells has largely been studied in differentiated CTLs. 
These studies have generally shown a co-stimulatory role for NKG2D, enhancing TCR-
stimulated effector function (Bauer, Groh et al. 1999, Groh, Rhinehart et al. 2001, Markiewicz, 
Carayannopoulos et al. 2005) or memory formation (Zloza, Kohlhapp et al. 2012, Wensveen, 
Lenartic et al. 2013). The effects of NKG2D signaling in the absence of TCR engagement is not 
well understood, but has been shown to induce immune synapse formation by mouse CTLs 
(Markiewicz, Carayannopoulos et al. 2005) and MHC-unrestricted killing by cytokine-activated 
human CTLs (Verneris, Karimi et al. 2004). Therefore, my finding that there is a role for 
NKG2D-H60a interaction during CD8
+
 T cell differentiation into CTL describes a new mode of 
NKG2D-ligand interaction, which dampens, rather than enhances, later CTL responses.  
 
In my in vitro experiments, there was a consistent decrease in TNFα, IL-10 and IFNγ production 
by CTL with either genetic knockout of NKG2D or antibody blockade of H60a with low levels 
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of stimulation. At the highest level of stimulation, IFNγ production was significantly decreased 
in a number of experiments. This decrease could potentially reflect a different cytokine response 
at very high levels of TCR stimulation. However, because this decrease was not significant when 
data from all experiments were combined,I did not investigate this further. Additionally, the 
consistently enhanced production of IFNγ by Klrk1
-/-
 adoptively transferred CD8
+
 T cells in vivo 
suggests that low to medium levels of TCR stimulation more closely reflect in vivo conditions.  
 
When the Markiewicz lab assessed diabetes incidence in Klrk1
-/-
 and wild type NOD mice, the 
results indicated a different effect of NKG2D genotype on diabetes incidence depending upon 
whether or not the mice were treated with microbiota-depleting antibiotics. Under SPF housing 
conditions, there was a detrimental role for NKG2D in NOD diabetes development. By contrast, 
when animals were treated with antibiotics, wild type NOD mice had delayed disease compared 
to Klrk1
-/- 
mice. This differential effect revealed a separate protective role for NKG2D. In 
addition, the lack of an effect of antibiotic treatment on disease incidence in Klrk1
-/-
 mice 
provides evidence for NKG2D genotype-dependent changes in the microbiota affecting NOD 
diabetes incidence. Antibiotic treatment resulted in a decrease in effector T cells in the pancreas. 
This is a probable mechanism by which diabetes development was decreased in antibiotic-treated 
compared with SPF-housed wild type mice. Further, it is likely that this decrease in effector T 
cells is what is responsible for the increased ability to observe the protective role NKG2D in 
diabetes development with antibiotic treatment. Taken together, these results indicate a 
detrimental influence of NKG2D on diabetes development in the gut, which involves the 
microbiota, and a separate effect independent of microbiota in which NKG2D dampens the NOD 
CTL cytokine response.  
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The Markiewicz lab observed the well-established sexual dimorphism in NOD diabetes 
incidence, with increased rates of diabetes in females compared to males (Makino, Kunimoto et 
al. 1981, Kikutani and Makino 1992, Pozzilli, Signore et al. 1993). Within SPF housed or 
antibiotic treated groups however, the effect of NKG2D was consistent between males and 
females. The mechanism by which NKG2D promotes NOD diabetes through interactions with 
microbiota was not explored in the current study, but warrants further investigation. This may be 
due to a lack of B1a cells in these mice (Lenartic, Jelencic et al. 2017), or interaction of other 
immune cells with NKG2D ligands, which are constitutively expressed by intestinal epithelial 
cells (Hue, Mention et al. 2004, Allez, Tieng et al. 2007, Eagle, Jafferji et al. 2009, Hansen, 
Holm et al. 2013). Additionally, further work remains to conclusively attribute the protective 
effect of NKG2D genotype in antibiotic treated animals to the effects of NKG2D-H60a 
interactions between CD8
+
 T cells. While my data do support this hypothesis, a definitive answer 
awaits the generation of a NOD H60a
-/-
 mouse, as well as CD8
+
 T cell conditional NOD 
NKG2D
-/-
 and NOD H60a
-/-
 animals. Finally, the  model of opposing pro- and anti-diabetic 
effects of NKG2D suggests that a lack of consensus from previous studies concerning the role of 
NKG2D in NOD diabetes may be the result of variation in co-housing practices and differences 
in microbiota between mouse colonies. 
 
 In summary, I found that NKG2D-H60a interaction between CD8
+
 T cells during NOD CTL 
differentiation in vitro resulted in decreased production of diabetogenic cytokines upon 
subsequent CTL activation. To my knowledge, this is the first report of a role for NKG2D-
NKG2D ligand interaction during differentiation of mouse CD8
+
 T cells into CTL rather than 
during the effector phase of differentiated CTL. Furthermore, these results describe a functional 
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role for NKG2D ligand expression by healthy murine CD8
+
 T cells.  Finding that NKG2D is 
protective in animals with depleted microbiota correlates with NKG2D signaling resulting in 
reduced cytokine production by NOD CTL. The additional observation that microbiota-depleting 
antibiotics profoundly affected NOD diabetes development in wild type, but not Klrk1
-/-
 animals 
demonstrates a separate effect in which NKG2D-dependent alterations in the microbiota promote 
disease development. Additionally, these data may have broader implications for the role of 
NKG2D-ligand interaction between T cells in modulating CD8
+
 T cell responses in both mice 





Chapter 3: NKG2D signaling within the pancreatic islets reduces NOD diabetes by 
enhancing CD8+ central memory cell generation 
 
Abstract 
NKG2D is implicated in autoimmune diabetes, with NKG2D ligand expression in pancreatic 
islets believed to play a detrimental role. Work from the Markiewicz lab has found that NKG2D 
and its ligands are present in human pancreata.  The expression of NKG2D and its ligands are 
increased in the islets of patients with type 1 diabetes. To directly assess the role of NKG2D in 
the pancreas, we generated NOD mice that express an NKG2D ligand in islet cells. Diabetes was 
not enhanced, but rather was reduced in these mice. The reduction corresponded with a decrease 
in the effector to central memory CD8
+
 T cell ratio. Further, NKG2D signaling enhanced central 
memory CD8
+
 T cell generation in vitro and diabetes protection by central memory CD8
+
 T cells 
in vivo. Taken together, these studies demonstrate that there is a protective role for central 
memory CD8
+
 T cells in autoimmune diabetes and that this protection is enhanced with NKG2D 
signaling.   
 
Introduction 
Early studies with the non-obese diabetic (NOD) mouse model led to the hypothesis that 
NKG2D signaling, induced by NKG2D ligands expressed on β-islet cells, enhances diabetes 
development (Ogasawara 2004, Markiewicz 2012). However, conflicting results were later 
reported which brought into question the importance of NKG2D to spontaneous autoimmune 
diabetes in this pre-clinical model (Guerra, Pestal et al. 2013, Trembath, Sharma et al. 2017). 
Our recent data implicate differential effects of NKG2D signaling induced by microbiota or islet 
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antigen (Trembath, Sharma et al. 2017) as a source of this controversy. Therefore, new 
experimental approaches are required to determine the various roles of NKG2D in diabetes.  
 
Previous work in the Markiewicz lab analyzed expression of the mRNAs encoding NKG2D and 
NKG2D ligands within human pancreatic islets from tissue sections donated to the Network for 
Pancreatic Organ Donors with Diabetes (nPOD) by people with type 1 diabetes, people with islet 
antigen-specific autoantibodies but not diabetic (likely pre-diabetic), or non-diabetic age and sex 
matched controls. Increased transcripts encoding both NKG2D and NKG2D ligands were 
detected in pancreatic islets harvested from type 1 diabetes donors, but not individuals positive 
for islet-specific antibody, compared with non-diabetic donors. These data indicate that increased 
NKG2D-ligand interactions within the pancreas are present in patients with type 1 diabetes, and 
demonstrate that NKG2D signaling in the pancreas is likely relevant to type 1 diabetes 
pathogenesis.  
 
Because both NKG2D and NKG2D ligands are expressed on immune cells in NOD mice 
(Zwirner, Fernandez-Vina et al. 1998, Molinero, Fuertes et al. 2002, Rabinovich, Li et al. 2003, 
Trembath and Markiewicz 2018), these proteins could not be eliminated specifically within the 
pancreas as a means to test the effects of NKG2D signaling in the pancreas on autoimmune 
diabetes development. Instead, NOD mice with constitutive expression of the mouse NKG2D 
ligand RAE1ε on β-islet cells, NOD.RIP-RAE1 mice, were generated. These mice were 
generated by moving a cre-inducible RAE1ε transgene generated previously (RIP-RAE1) 
(Markiewicz, Wise et al. 2012) and a rat insulin promoter (RIP)-cre transgene onto the NOD 
background, followed by interbreeding of these two strains to generate NOD mice with 
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constitutive expression of RAE1ε in the pancreatic islets (NOD.RIP-RAE1ε). It was 
subsequently found that despite earlier infiltration of immune cells into the pancreas, these mice 
developed significantly less diabetes compared to wild type NOD mice. In addition, this 
difference was lost in NKG2D knockout NOD.RIP-RAE1 mice, demonstrating a dependence 
upon NKG2D.  
 
Here, I find a reduced ratio of effector and effector memory CD8
+
 T cells (Teff + em) to central 
memory CD8
+
 T cells (Tcm), corresponding with this previously observed reduction in diabetes. 
Correlating with these in vivo data, we found that stimulation of NKG2D on human and mouse 
CD8
+
 T cells during in vitro activation increased the generation of CD8
+
 Tcm. Finally, we found 
that CD8
+
 Tcm actively suppress NOD diabetes development in vivo. Taken together, these 
results indicate that NKG2D ligand expression in pancreatic islets protects against autoimmune 
diabetes development by enhancing the generation of a protective CD8
+





 Teff + em:Tcm ratio in RIP-RAE1ε NOD mice 
I compared the immune infiltrate in the pancreas of NOD.RIP-RAE1ε and RAE1- littermates 
(NOD.PCCALL and NOD. RIP-Cre) mice at 12 weeks of age, a time at which both of these 
strains have similar insulitis but have not yet developed diabetes. I focused on T cells and NK 
cells, as these are the cells that express NKG2D in the wild type  NOD islets (Trembath, Sharma 
et al. 2017). I found similar numbers of T cells, including CD4
+
 T and CD8
+
 T, as well as NK 
cells, in the pancreas and spleen of NOD.RIP-RAE1ε and RAE1- littermates (NOD. PCCALL 









) and a greater 
percentage of CD8
+




) in the 
pancreas (Fig. 14A-C), resulting in a decreased CD8+ Teff + em:Tcm ratio compared to RAE1- 
littermates (NOD. PCCALL and NOD.RIP-cre) mice (Fig. 14D). The CD8
+
 Teff + em:Tcm ratio 
was even lower in the spleen of NOD.RIP-RAE1ε mice (Fig. 14H-K), and this difference was 
consistently observed in both male and female mice. Demonstrating NKG2D signaling was 
required for this effect on CD8
+
 T cell populations, no difference was observed between 
NOD.RIP-RAE1ε-Klrk1
-/-







) mice (Fig. 14E,F, L, and M). In contrast to these CD8
+
 T cell population alterations, 
we did not observe a difference in the CD4
+
 Teff + em:Tcm ratio when comparing NOD.RIP-RAE1 
and RAE1- littermates (NOD. PCCALL and NOD.RIP-cre) (Fig. 14G and 14N) These data 






Figure 14: Decreased ratio of CD8
+
 Teff + Tem to Tcm in RIP-RAE1ε NOD mice. (A and H) 




 cells from the (A) pancreas or (H) 
spleen of a RIP-RAE1 (top panel) or control (bottom panel) mouse showing CD44 and CD62L 
expression. The numbers shown are the percentage of cells present in each quadrant of the dot 

















 (naïve) in the (B) pancreas or (I) spleen of RIP-RAE1ε 













 (naïve) in the (C) 
pancreas and (J) spleen of RIP-RAE1ε mice (n=22) and control (RIP-Cre and PCCALL) mice 
(n=19). (D and K) The ratio of CD8
+
 Teff + Tem:Tcm in the (D) pancreata and (K)  spleen of RIP-
RAE1 and control (RIP-Cre and PCCALL) mice. (E and L) The ratio of CD4+ Teff + Tem:Tcm in 
the (E) pancreata and (L) spleen of RIP-RAE1 and control (RIP-Cre and PCCALL) Klrk1
-/-
 













 (naïve) in the (F) pancreas and (M) spleen of RIP-RAE1ε/ Klrk1
-/-
 
(n=15) and control (RIP-Cre and PCCALL)/Klrk1
-/-
 (n=20) mice. (G and N)  The ratio of CD4
+
 
Teff + Tem:Tcm in the (G) pancreata and (M)  spleen of RIP-RAE1 (n=22) and control (RIP-Cre 




 Tcm delay NOD diabetes development  
I hypothesized that the greater number of CD8
+
 Tcm in the NOD.RIP-RAE1 was directly 
responsible for the decreased diabetes development in these mice.  To test this, I purified CD8
+
 








) populations from non-diabetic NOD mice. I 
then adoptively transferred Teff + em, Tcm, or Teff + em and Tcm, along with CD8
+
 T cell-depleted 
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NOD splenocytes, into NOD.Scid recipient mice (Fig. 15A). I measured blood glucose levels 
weekly, and time determined time to diabetes within each experiment relative to the first mouse 
to become diabetic. The mice that received the CD8
+
 Teff + Tem cells developed diabetes 
significantly earlier compared with the ones that received Tcm or Tcm+ Teff + em (Fig. 15B). These 
results demonstrate that NOD CD8
+
 Tcm not only are less diabetogenic compared CD8
+
 Teff + Tem, 





Figure 15: CD8+ Tcm delay NOD diabetes development. (A) Schematic of adoptive transfer 
experimental design. M: million. (B) The number of days to diabetes in NOD.SCID recipient 
mice. The day the first mouse in each experiment developed diabetes was called “day 0”. The 
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data shown are combined data from five independent experiments. Open points denote mice that 
were not yet diabetic at the time of submission. *p< 0.05 and **p< 0.001 in Log-Rank test. 
 
NKG2D signaling during NOD CD8
+
 T cell activation in vitro drives Tcm generation and 
increases expression of PD-1 
NKG2D has been shown to be important in CD8
+
 T cell memory formation in other mouse 
strains, especially CD8
+
 Tcm (Zloza, Kohlhapp et al. 2012, Wensveen, Lenartic et al. 2013, Perez, 
Prajapati et al. 2019).  I therefore hypothesized that NKG2D signaling directly in NOD CD8
+
 T 
cells was responsible for the increase in CD8
+
 Tcm generation in the NOD.RIP-RAE1 mice. To 
test  this, I purified CD8
+
 T cells from NOD mice and activated them in vitro with splenocytes 
from B6.RAE1ε, which have ubiquitous transgenic expression of RAE1ε (Cheney, Wise et al. 
2012), or control B6 splenocytes.  Similar to our observation with CD8
+
 T cell populations in 
vivo in the NOD.RIP-RAE1 mice (Fig. 12 and 13), NKG2D stimulation during in vitro 
activation with the B6.RAE1 splenocytes resulted in a significantly reduced ratio of Teff + em to 
Tcm CD8
+
 T cells (Fig. 16). 
 
I also assessed PD-1 expression by the resulting CD8
+
 T cells after stimulation on splenocytes 
expressing Rae-1ε or control. The immune inhibitory receptor PD-1 plays an important role in 
suppressing autoimmune diabetes development (Ansari, Salama et al. 2003, Clotman, Janssens et 
al. 2018), and has been found to be decreased in children with new onset type I diabetes 
(Granados, Draghi et al. 2017). I found that NKG2D stimulation significantly increased the 
expression of PD-1 on NOD CD8
+
 T cells alone (Fig. 17 A and B) or with the addition of IL-15 
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(Fig. 17 C and D). Analysis of PD-1 expression by the CD8
+
 Tcm population showed a similar 







Figure 16: NKG2D signaling in NOD CD8+ T cells increases CD8
+
 Tcm generation. (A) 




 cells showing 
CD44 and CD62L expression. The numbers shown are the percentage of cells present in each 













 (Teff + em) after activation in vitro in the 
presence of RAE1+
 
or RAE1- splenocytes. (D) The ratio (mean +/- STD) of NOD CD8+ Teff + 
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em:Tcm generated after activation in vitro in the presence of RAE1+
 
or RAE1- splenocytes. 




Figure 17: NKG2D stimulation in NOD CD8
+
 T cells increases PD-1 expression. NOD CD8
+
 
T cells activated with anti-CD3 and irradiated Rae-1ε expressing B6 splenocytes or Rae-1ε (-) 
control with (A and B) or without (C and D) the addition of 20ng/mL IL-15. (A and B) 
Representative flow histograms showing PD-1 expression on CD8
+
 T cells on day 5 following 
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activation with the indicated splenocytes. (B and D) mean fluorescence index (MFI) of three 
technical replicates. These results are representative of 3 independent experiments. *p<0.05.  
 
 
NKG2D signaling during human CD8
+
 T cell activation drives Tcm generation 
I wanted to determine if NKG2D stimulation of human CD8
+
 T cells similarly decreases the ratio 
of Teff + em to Tcm CD8
+
 T cells. To do this, I purified total CD8
+
 T cells from human peripheral 
blood and activated these cells in vitro for 5 days in the presence of activating anti-NKG2D or 
control antibody. Similar to the mouse CD8
+
 T cells, I found that NKG2D stimulation during in 
vitro activation significantly reduced the ratio of human CD8
+
 Teff + em to Tcm (Fig. 18 A and B). I 
next sought to determine whether NKG2D stimulation was driving CD8
+
 Tcm generation during 
the initial activation of naïve CD8
+
 T cells, or if it was expanding and enhancing the survival of a 
previously activated population. To do this, I repeated the experiment with naïve human CD8
+
 T 
cells. I found that NKG2D stimulation similarly increased the generation of Tcm cells from naïve 
CD8
+






Figure 18: NKG2D signaling in human CD8+ T cells increases CD8+ Tcm generation. (A 
and C) Representative flow cytometry data gated on in vitro-activated human (A) total or (C) 
naïve CD3+CD8+ cells showing CCR7 and CD45RO expression. The numbers shown are the 















in vitro in the presence or absence of an activating anti-NKG2D antibody. These data are the 
combined results of five independent experiments. (D) The ratio of human CD8
+
 Teff + em:Tcm 
generated after activation of naïve CD8+CD3+ cells in vitro in the presence of or absence of an 
activating anti-NKG2D antibody. These data are the combined results of five independent 






NKG2D signaling during human CD8
+
 T cell activation increases generation of regulatory CD8
+
 




 Tcm population is heterogeneous, and contains sub-populations if CD8
+
 Tregs (Li, Xie 
et al. 2014). To determine if NKG2D stimulation specifically increased CD8
+
 T cells with a 
regulatory phenotype, I activated human CD8
+
 T cells in vitro with plate bound anti-CD3 and 
anti-CD28, in the presence of plate bound activating anti-NKG2D antibody or control. On day 5 
I assessed the CD8
+




 cells within 




 Tcm phenotype cells has been shown to be 






 Tregs (Li, Xie et al. 2014) which have been shown 
to be beneficial in autoimmune diabetes (Tsai, Shameli et al. 2010). As before, I found that 
NKG2D stimulation caused a trend of increased CD8
+
 Tcm population (Fig. 19A). In addition, I 
found that within the CD8
+






 Tregs also 
trended higher with NKG2D stimulation (Fig. 19B). I then asked if NKG2D stimulation was 






 Tregs, or if NKG2D stimulation was enhancing 
survival or expansion of an existing population. I therefore activated naïve human CD8
+
 T cells 
in vitro with plate bound activating anti-NKG2D antibody, or control. Because IL-15 has been 
shown to increase memory CD8
+
 T cell populations (Schluns, Williams et al. 2002, Weng, Liu et 
al. 2002, Berard, Brandt et al. 2003), we activated cells with or without IL-15. As shown 
previously, NKG2D stimulation enhanced generation of CD8
+
 Tcm cells (Fig. 18). Interestingly 
both NKG2D and IL-15 increased Tcm generation, and appeared to act in a combinatorial fashion 
with NKG2D and IL-15 together showing a trend towards increased Tcm generation (Fig. 19 C 










 Tregs represented a relatively consistent percentage of the 
Tcm population treatment groups (fig 19 E and F), but increased in total number proportionally 






Figure 19: NKG2D stimulation increases CD8
+
 Treg generation in vitro.   
(A and B) Total human CD8
+
 T cells isolated from PBMCs by negative selection and activated 
in vitro with plate bound anti-CD3 and anti-CD28 with plate bound activating anti-hNKG2D or 
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.(C-H) Combined data from at least 5 independent experiments with naïve human 
CD8
+
 T cells isolated from PBMCs by negative selection activated as in (A and B) with or 
















NKG2D and NKG2D ligand expression has been reported in the pancreas of NOD mice 
(Ogasawara, Hamerman et al. 2004, Trembath, Sharma et al. 2017). However, the expression of 
NKG2D and NKG2D ligands in the human pancreas had not been previously assessed. The 
Markiewicz lab demonstrated that mRNAs encoding NKG2D and NKG2D ligands are detectable 
in human pancreatic islets, with increased expression in patients with type 1 diabetes compared 
with age and sex matched non-diabetic controls. These findings establish that NKG2D signaling 
likely occurs in the pancreas during type 1 diabetes, supporting continued study of NKG2D 
signaling in the pancreas in diabetes pathogenesis.  
 
NKG2D has been implicated in the development of type 1 diabetes. How it affects disease 
development, and whether these effects are positive or negative has been a point of uncertainty. 
As discussed in Chapter whatever, I  showed a protective effect of NKG2D signaling on CD8
+
 T 
cells in NOD diabetes, but the Markiewicz lab also found evidence that NKG2D signaling in the 
gut may have detrimental effects on disease development (Trembath, Sharma et al. 2017). These 
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findings suggest that NKG2D signaling plays different roles in autoimmune diabetes progression 
in different anatomical locations. In this study, I endeavored to more closely assess the role 
played by NKG2D signaling within the pancreas in autoimmune diabetes.  
 
Because both NKG2D and its ligands are expressed on immune cells (Trembath and Markiewicz 
2018), we could not eliminate these proteins specifically within the pancreas. Therefore, to test 
the effect of NKG2D signaling in the pancreas, we instead increased NKG2D signaling 
specifically within the pancreatic islets. In the NOD.RIP-RAE1ε model, NKG2D signaling is 
selectively increased in the islets by transgenic expression of RAE1ε using the rat insulin 
promoter. In this model, it was the Markiewicz lab previously showed reduced diabetes 
development by NOD.RIP-RAE1 mice. This diabetes reduction correlated with a decreased 
ratio of CD8
+
 Teff + em cells to CD8
+
 Tcm. Given the central role CD8
+
 Teff cells play in 
autoimmune diabetes pathology (Tsai, Shameli et al. 2008, Burrack, Martinov et al. 2017), it is 
not surprising that reduction in these cells correlated with the previously observed reduction in 
diabetes development. In contrast, the increase in CD8
+
 Tcm in NOD.RIP-RAE1ε mice was 
somewhat surprising. This increase is unlikely simply a reflection of the lower percentage of 
NOD.RIP-RAE1ε mice on their way to developing diabetes. If this was the case, we would have 
observed a similar increase in CD8
+
 Tcm in male NOD mice, which have a lower diabetes 
incidence compared with female NOD mice, but we did not. Therefore, our data support the 
hypothesis that this increase in CD8
+
 Tcm does not just correspond to the reduced diabetes in both 
female and male NOD.RIP-RAE1ε compared with NOD, but is the cause for the RAE1ε-
mediated reduction. This hypothesis is further supported by the results of the NOD.Scid adoptive 
cell transfer studies that demonstrated suppression of diabetes development by CD8
+




The cell adoptive transfer studies revealed that CD8
+
 Tcm not only blocked diabetes onset but 




 Teff + em cells correlate with islet pathology 
(Chee, Ko et al. 2014), and CD8
+
 Teff cells play a central role in autoimmune diabetes pathology 
(Tsai, Shameli et al. 2008, Burrack, Martinov et al. 2017). In contrast, CD8
+
 Tcm have reduced 
cytotoxicity and effector functions (Farber, Yudanin et al. 2014), correlating with reduced 
diabetes transfer by these cells. However, the delay in diabetes I observed with co-transfer of 
CD8
+
 Tcm cells with CD8
+
 Teff + em demonstrates a regulatory effect of the CD8
+
 Tcm population. 
Such a regulatory role for NOD CD8
+
 Tcm was suggested by previous studies performed by 
Santamaria and colleagues using transgenic T cell systems (Khadra, Tsai et al. 2010, Tsai, 
Shameli et al. 2010, Shameli, Clemente-Casares et al. 2011), however this had not been 
investigated in parental NOD mice. Tcm can also be precursors to Teff cells (Sallusto, Geginat et 
al. 2004). Therefore, the protective cells are likely a subset of the CD8
+
 Tcm population. CD8
+
 
Tcm are a heterogeneous population, which have been shown in other mouse strains to contain a 
subpopulation of immune regulatory CD8
+
 T cells (Tregs) (Li, Xie et al. 2014). In humans, one 
of these Tcm CD8
+




 (Li, Xie et al. 2014), 
the population and number of which trended strongly upwards with NKG2D stimulation in vitro. 
This observation is consistent with the significant increase in PD-1 expression by mouse T cells 
with NKG2D stimulation in vitro. PD-1 has been shown to be important in suppressing NOD 
diabetes (Ansari, Salama et al. 2003, Clotman, Janssens et al. 2018), as well as type 1 diabetes in 
humans (Schroder, Khattar et al. 2015)  Future studies will need to be performed to determine 
the identity of the protective NOD CD8
+
 Tcm population, but our results demonstrate this 




My results indicate that the reduced Teff + em to Tcm ratio in NOD.RIP-RAE1ε mice is due to 
enhanced NKG2D signaling directly in CD8
+
 T cells. I found that NKG2D stimulation during in 
vitro activation of NOD CD8
+
 T cells drove a similar decrease in the ratio of Teff + Tem to Tcm as 
observed in NOD.RIP-RAE1ε mice. This finding that NKG2D stimulation drives a shift towards 
CD8
+
 Tcm generation in the NOD mouse is consistent with a role for NKG2D in promoting 
memory cell development, particularly Tcm, demonstrated by others with C57BL/6 mice (Zloza, 
Kohlhapp et al. 2012, Wensveen, Lenartic et al. 2013, Wensveen, Jelencic et al. 2018, Perez, 
Prajapati et al. 2019). Importantly, demonstrating the translatability of the findings of these 
mouse studies to the human, I showed that NKG2D signaling during the activation of human 
CD8
+
 T cells also favors Tcm generation over Tem + eff. 
 
Initial reports demonstrated that RAE-1 family members were expressed by β-islet cells in NOD 
mice (Ogasawara, Hamerman et al. 2004), that RAE1 expression by β-islet cells enhanced the 
recruitment of  CD8
+
 T cells to the islets (Markiewicz, Wise et al. 2012), and that NKG2D 
inhibition reduced NOD diabetes (Ogasawara, Hamerman et al. 2004). This led to the hypothesis 
that inappropriate NKG2D ligand expression by β-islet cells contributed to autoimmune diabetes 
development or progression. However, the Markiewicz lab and others have been unable to detect 
RAE1 expression in the pancreas of NOD mice, and do not detect NKG2D ligand expression by 
β-islet cells themselves in our NOD colony (Angstetra, Graham et al. 2012, Carrero, Calderon et 
al. 2013, Trembath, Sharma et al. 2017). The reason for these differing reports of RAE1 
expression in islets of NOD mice from different mouse colonies is unclear, but may be the result 
of variation due to genetic drift or differences in microbiota composition. Regardless, the lack of 
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RAE1 expression in the islets of mice in our NOD colony afforded us a model with which we 
could directly test the hypothesis that NKG2D ligand expression on β-islet cells promotes NOD 
diabetes. In contrast to the original hypothesis, our data demonstrate that RAE1ε expression by 
islet cells is protective against NOD diabetes and acts via interaction with NKG2D. These data 
may seem surprising given that NKG2D ligand expression canonically targets cells for killing 
(Lanier 2015). However, this delay in diabetes in NOD.RIP-RAE1ε mice is consistent with my 
studies demonstrating a protective role for NKG2D signaling in NOD mice (Trembath et al. 
2017), and a role for NKG2D signaling in memory CD8
+
 T cell generation (Zloza, Kohlhapp et 
al. 2012, Wensveen, Lenartic et al. 2013, Perez, Prajapati et al. 2019). These results indicate that 
the diabetes promoting effect of NKG2D signaling observed in some NOD colonies (Ogasawara, 
Hamerman et al. 2004, Van Belle, Ling et al. 2013) occurs outside of the pancreas, which other 
studies in the Markiewicz lab suggest is in response to microbiota antigen (Trembath, Sharma et 
al. 2017).  Further studies will be required to determine the identity of such disease-promoting 
NKG2D signaling. In addition, the Markiewicz lab reported that the NKG2D ligand H60a is 
endogenously expressed by infiltrating activated T cells in the NOD pancreas (Trembath, 
Sharma et al. 2017). Future studies will be required to determine if this endogenous NKG2D 
ligand expression in the pancreas also induces CD8
+
 Tcm generation and diabetes protection.   
 
Although constitutive exposure to ligand can lead to NKG2D downregulation and dysfunction 
(Oppenheim, Roberts et al. 2005, Wiemann, Mittrucker et al. 2005), the Markiewicz lab data are 
consistent with enhanced, not reduced, NKG2D signaling in pancreatic islets results in reduced 
diabetes in the NOD.RIP-RAE1ε mice. While reduced NKG2D expression on CD8
+
 T cells of 
NOD.RIP-RAE1ε mice in the pancreas was observed, NKG2D expression by CD8
+
 T cells in the 
66 
 
spleen was unaffected. This is indicative of increased local NKG2D signaling, as NKG2D is 
internalized upon ligand engagement and signaling (Molfetta, Quatrini et al. 2016), and recovers 
upon removal of ligand stimulation (Oppenheim, Roberts et al. 2005).  Additionally, the reduced 
diabetes in NOD.RIP-RAE1ε mice correlates with the increased rate of diabetes in NKG2D-
deficient NOD mice observed with treatment with gut microbiota-depleting antibiotics 
(Trembath, Sharma et al. 2017). Finally, my in vitro data demonstrate that NKG2D signaling in 
CD8
+
 T cells enhances Tcm generation, which correlates with the increased CD8
+
 Tcm generation 
observed in NOD.RIP-RAE1 mice. NKG2D is not expressed on mouse CD8
+
 T cells until 3-4 
days following initial activation (Markiewicz, Carayannopoulos et al. 2005, Trembath, Sharma et 
al. 2017). This is a time when these cells start to migrate to the site of antigen (Kinjyo, Qin et al. 
2015). Taken together, these data support the conclusion that NKG2D signaling in islet-specific 
CD8
+
 T cells present in the islets during activation enhances Tcm generation. Interestingly, a 
previous study demonstrated that expression of a high level of soluble RAE1ε to the NOD 
pancreas led to reduced diabetes (Joo, Jeong et al. 2012). Given the data demonstrating inhibition 
of NKG2D signaling by soluble ligand (Zingoni, Molfetta et al. 2018), this was hypothesized to 
be due to reduced NKG2D signaling within the pancreas on islet-specific T cells. However, no 
mechanistic studies were performed. Taken in light of our data with cell-bound RAE1ε, it is 
interesting to speculate that this soluble RAE1 may have instead been carried outside of the 
pancreas and inhibited NKG2D signaling in response to microbiota antigen.  
 
In conclusion, we found an increased presence of NKG2D and NKG2D mRNA within the 
pancreatic islets of patients with type 1 diabetes and developed a novel mouse model, NOD.RIP-
RAE1ε, to test the effects of NKG2D signaling specifically within the pancreas. We showed that 
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increased NKG2D signaling within the pancreas of NOD mice had a protective effect, delaying 
diabetes in NOD.RIP-RAE1ε mice. This correlated with a decrease in the ratio of CD8
+
 Teff + em 
cells to Tcm cells in NOD.RIP-RAE1ε mice. We demonstrated that NKG2D signaling on CD8
+
 T 
cells drives a similar shift in both human and NOD CD8
+
 T cell populations in vitro. Finally, we 
found that CD8
+
 Tcm cells transferred significantly less NOD diabetes than CD8
+
 Teff + em cells, 
and had a protective effect, delaying diabetes when co-transferred with CD8
+
 Teff + em cells. We 
therefore propose a protective role for NKG2D signaling within the pancreas in autoimmune 
diabetes, by increasing a protective CD8
+
 Tcm population relative to the more pathogenic CD8
+
 
Teff + em population. These findings reiterate the importance of NKG2D in autoimmune diabetes, 
and further stress the importance of anatomical location when determining the role NKG2D 










Chapter 4: Further Investigations into NKG2D ligand expression by CD8
+
 T cells 
Expression profile of H60a differs between NOD and Balb/c CD8
+
 T cells upon activation 
in vitro.  
 
I previously showed expression of H60a by NOD CD8
+
 T, which is increased upon activation in 
vitro. In addition, I showed that engagement of H60a by NKG2D on CD8
+
 T cells during 
differentiation alters the populations and cytokine production of mature CD8
+
 T cells. I therefore 
hypothesized that NKG2D stimulation on CD8
+
 T cells during differentiation may be an 
important mechanism for regulating CD8
+
 T cell function. The H60a gene is not functionally 
expressed by C57BL/6 mice (Takada, Yoshida et al. 2008), however expression of the mouse 
NKG2D ligand Rae-1ε has been found to be expressed by endothelial cells within lymph nodes. 
This expression may provide similar NKG2D stimulation during CD8
+
 T cell differentiation in 
the C57BL/6 strain. Balb/cJ mice do however possess a functional H60a gene. I therefore wanted 
to see if H60a was similarly expressed by Balb/cJ CD8
+
 T cells. To do this, I harvested 
splenocytes from NOD or Balb/cJ mice and activated them in vitro with soluble anti-CD3 
antibody in the presence of absence of 2ug/mL anti-NKG2D blocking antibody. Cells were then 
assessed daily for expression of NKG2D ligands by flow cytometry gating on CD8
+
 T cells. The 
only NKG2D ligand we readily observed on both NOD and Balb/c CD8
+
 T cells was H60a. In 
the absence of anti-NKG2D antibody blockade, both NOD and Balb/c CD8
+
 T cells showed low 
but detectable expression of H60a on day 0, which increased upon activation, and peaked at day 





 T cells retained markedly higher H60a expression compared Balb/c CD8
+
 T 
cells whose expression of H60a decreased to levels near those seen on day 0 (Fig. 20). Antibody 
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blockade of NKG2D during culture resulted in less down regulation of H60a after day 2 by both 
NOD and Balb/c CD8
+
 T cells, with the effects being most pronounced on CD8
+
 T cells from 
Balb/c mice (Fig. 20). While we did not further investigate this differential regulation of H60a by 
NOD vs. Balb/c CD8
+
 T cells, it remained consistent over three experiments.  
 In mice, NKG2D is not expressed by naïve CD8
+
 T cells, and becomes expressed 2-3 
days after activation (Markiewicz, Wise et al. 2012, Lanier 2015, Trembath, Sharma et al. 2017). 
Therefore, the decreased in H60a expression we observed coincides with the time when NKG2D 
becomes present on the cell surface. A decreased reduction in H60a after with NKG2D blockade 
further suggests that NKG2D signaling contributes to the regulation of H60a expression by CD8
+
 
T cells. Further, it has been shown that NOD mice have a defect in NKG2D signaling 
(Ogasawara, Hamerman et al. 2003), which may play a role in the increased expression of H60a 
by NOD vs. Balb/c CD8
+
 T cells by day 5 following activation in vitro. Whether this observation 
is a result of defective NKG2D signaling in NOD mice, or may contribute to NOD NKG2D 
dysfunction has yet to be determined. It has been found that H60a mRNA is negatively regulated 
by IFNγ via the 3’UTR (Zhang et al. 2010). While we did not assess IFNγ production while 
conducting these experiments, this could further contribute to changes in H60a expression.  The 
functional implications of this differential H60a expression pattern were not studied, but may 
lead to further insights into the importance of NKG2D-NKG2D ligand signaling on CD8
+






Figure 20: Expression of H60a differs between NOD and Balb/c CD8
+
 T cells upon 
activation in vitro. CD8
+
 T cells from NOD and Balb/c mice purified by negative selection and 
activated in vitro using plate bound anti-CD3 and anti-CD28 in the presence of soluble anti-
NKG2D blocking antibody or control. Cells were assessed daily, through day 4, for H60a 






The NKG2D ligand H60a is expressed by NOD thymocytes 
My study of H60a expression on NOD CD8
+
 T cells was primarily focused on cells harvested 
from spleens and lymph nodes. In doing so I captured CD8
+
 T cell populations ranging from 
naïve to memory. It is worth noting that I also observed expression of H60a by NOD 
thymocytes. I dissociated thymi from 6-8 week old NOD mice and analyzed immune cell 
populations by flow cytometry. I found expression of H60a NOD thymocytes. H60a was 
primarily expressed by CD3
+
 T cells, though there was some expression of H60a by the CD3
-
 
population (Fig. 21). NKG2D ligands have been previously described in the thymus of Balb/c 
mice (Diefenbach, Jamieson et al. 2000, Li, Rabinovich et al. 2005), however this expression 
was observed with an NKG2D tetramer, and these studies did not identify a particular NKG2D 
ligand. mRNA for the mouse NKG2D ligand MULT1 was found to be expressed by thymocytes 
(Nice, Coscoy et al. 2009), but the protein was not found to be expressed on the cell surface, and 






Figure 21: NOD Thymocytes express the NKG2D ligand H60a. Representative flow plots 
showing thymocytes from 6-8 week old NOD mice stained for CD3 and H60a or control. 










NOD diabetes incidence is not significantly different between NOD 8.3 NKG2D knockout 
vs. NOD 8.3 NKG2D wild type animals. 
Data from the Markiewicz lab suggests that NKG2D has pro-diabetic and anti-diabetic effects on 
NOD diabetes, acting through at least two separate mechanisms. Previous data from our lab 
points to interactions between NKG2D bearing cells and the microbiota as playing a role in 
diabetes development. My work has described a role for NKG2D signaling specifically in CD8
+
 
T cells, reducing the CTL immune response. Because CD8
+
 T cells are important mediators of 
pancreatic β-cell destruction, I sought to further determine the effects of NKG2D on CD8
+
 T 
cells on NOD diabetes. To do this, I used NOD 8.3 mice, whose CD8
+
 T cells have transgenic T 
cell receptors specific for a known auto antigen, and develop NOD diabetes at an accelerated rate 
(Verdaguer, Schmidt et al. 1997). Because auto reactive CD8
+
 T cells are the main drivers of 
accelerated diabetes in this model, I hypothesized that this model would highlight the effects of 
NKG2D specifically in CD8
+
 T cells in NOD diabetes. I therefore used NOD 8.3 NKG2D 
knockout animals which I generated by crossing NOD 8.3 mice with our NOD NKG2D 
knockout animals. Blood glucose was then monitored weekly. Diabetes incidence was not 
significantly different between NKG2D WT (n=23) and KO (n=19) males, or NKG2D WT 
(n=15) and KO (n=17) females (Fig. 22). These findings differ from our earlier observations in 
non-TCR transgenic NOD mice in which NKG2D influenced NOD diabetes development via 
multiple mechanisms (Trembath et al. 2017). It is possible that effects of NKG2D are not 
observed in this model due to the accelerated diabetes, and specific monoclonal CD8
+
 T cell 





Figure 22: NOD diabetes is not significantly different between NKG2D deficient and wild 
type NOD 8.3 mice.  Diabetes incidence in (A) male NOD 8.3 NKG2D KO (n=19) and WT 
(n=23) and (B) female NOD 8.3 NKG2D KO (n=17) and WT (n=15) animals.  
 
 
Generation of NOD mice genetically deficient in H60a – establishing the NOD.B6 H60a 
mouse line 
H60a was the only NKG2D ligand I observed expressed by NOD CD8
+
 T cells. However, NOD 
mice do posses functional genes for other NKG2D ligands. In order to determine if the observed 
effects of NKG2D knockout on CD8
+
 T cells and NOD diabetes were a result of NKG2D 
interactions with H60a, we sought to generate NOD mice deficient in H60a. Because of the 
potential for introducing unintended effects during the genetic manipulation of any mouse strain, 
the lab chose to generate two separate lines of H60a deficient NOD mice. One strain was 




H60a pseudo gene (Zhang, Hardamon et al. 2011) onto the NOD background. Here I will discuss 
generation the latter, NOD.B6 H60a mouse line.  
 
Expression of H60a has been observed on cells from various mouse strains, including Balb/b, 
Balb/c, and 129/Sv (Malarkannan et al. 1998; Samarakoon et al. 2009; Zhang et al. 2010). 
However, the widely used C57BL/6 mouse possesses a truncated H60a pseudo gene, which does 
not produce a functional protein (Malarkannan et al. 1998; Zhang et al. 2010). We took 
advantage of this naturally non-functional C57BL/6 H60a pseudo gene, and Transferred the 
C57BL/6 H60a pseudo gene to the NOD genetic background. The resultant mice are congenic 
mice that possess the C57BL/6 H60a pseudo gene which are at least 98.23% NOD based on SNP 





Figure 23: Establishing the C57B/6 H60a gene on the NOD background. (A) Summary of 
single nucleotide polymorphism (SNP) analysis of the mouse used to generate the NOD.B6 H60a 
mouse line. Green indicates percentage of SNPs homozygous for the NOD mouse background, 
with purple showing the percentage of SNPs heterozygous for both the NOD and C57BL/6 
background. There were no SNPs which were homozygous for the B6 background. (B) 
Chormosome map of the same mouse showing distribution of SNPs with the same color 
schematic. SNP analysis was performed by DartMouse. 
 
Preliminary characterization of NOD.B6 H60a CD8
+
 T cells  
Generation of the NOD.B6 H60a mouse allowed us to test whether loss of H60a affected CD8
+
 T 
cell function in a similar manner to genetic knockout of NKG2D. To do this, we again isolated 
CD8
+
 T cells from NOD.B6 H60a or control animals, and activated them in vitro with plate 
bound anti-CD3 and anti-CD28. After 5 days, cells were re-stimulated with varying 
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concentrations of plate bound anti-CD3. After 20 hours, supernatant cytokines were assessed 
using a BD cytometric bead array. We found that with the intermediate concentration of anti-
CD3 for re-stimulation, CD8
+
 T cells from NOD.B6 H60a
-/-
 animals produced more TNFα and 
IFNγ compared to control. This trend was observed in 4 separate experiments, but in combined 
fold change data did not reach statistical significance (Fig. 24), which would likely be achieved 
with further repetition. Despite this, these data are consistent with our earlier results showing 
increased cytokine production by CD8
+
 T cells deficient in NKG2D (Fig. 6), or with anti-H60a 
antibody blockade (Fig. 10) 
 
 




 T cells produce increased TNFα and IFNγ upon re-
stimulation in vitro.  Production of TNFα and IFNγ by NOD.B6 H60a
-/-
 and NOD.B6 H60a
+/+
 
CTL after re-stimulation on varying concentrations of plate bound anti-CD3. Supernatant 
78 
 
cytokines were measured by BD cytometric bead array, and are presented as fold change vs. 
control (NOD.B6 H60a
+/+
). These are combined data from at least 3 independent experiments.  
 
 
Transcription factors AP2, KLF4, Prox1, and Foxo1 are candidates that may bind and 
regulate Rae-1 expression.  
 
In their most studied role, NKG2D ligands are described as “stress ligands” and become 
expressed by cells undergoing cellular stress such as viral infection or cancerous transformation. 
Despite this, there is lack of consensus as to which signals and transcription factors lead to 
NKG2D ligand expression. Factors including DNA damage, LPS treatment, heat shock, IFNγ, 
and cellular proliferation, reviewed in (Champsaur and Lanier 2010, Raulet, Gasser et al. 2013), 
have been reported. Given the CD8
+
 T cell modulating role for NKG2D ligand expression by 
immune cells that I uncovered, I sought to determine what signals regulate NKG2D ligand 
expression. To do this, I used a commercial transcription factor binding assay, and quarried 
which transcription factors bound to the promoter region of the mouse Raet1 gene. Using the 
Raet1 promoter region I PCR-amplified from a Rae-1-expressing mouse embryonic fibroblast 
cell line, identified the transcription factors AP2, KLF4, Prox1, and Foxo1 as positive hits for 
binding the Rae-1 promoter (Table 2). Sequence analysis of the Rae-1 promoter region revealed 
exact matches to sequences known to be bound by AP2, KLF4, and Prox1 (Table 2). Despite 
positive hits for Foxo1 binding in both trials, the Rae-1ε promoter region did not contain a 
known Foxo1 binding sequence (Table 2). Further verification and investigation will be needed 
to determine if these transcription factors play a role in the expression of Rae-1ε and other 
NKG2D ligands.  
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Table 2: Candidate transcription factors positive for binding the Rae-1ε promotor 
Transcription 
Factor 
Known Sequence Specificity Appearance in Rae-1ε Promoter 
AP2 (TFAP2)  GCCN3-4GGC Yes – Exact match 
KLF4 CACCC 
Yes – Exact reverse complement match, 




Yes – Multiple Exact 
Foxo1 TT[G/A]TTT[T/A][G/C] No 
 
 
NKG2D stimulation of mouse CD8
+
 CTL with Rae-1 alters mRNA expression profile.  
 
NKG2D is best known studied for its role as an activating receptor on NK cells, where 
engagement of NKG2D ligand is sufficient to activate lytic granule release and target cell killing 
(Lanier 2015). The role of NKG2D on CD8
+
 T cells has been primarily described as co-
stimulatory, enhancing the response to TCR signaling (Wensveen, Jelencic et al. 2018). I 
therefore asked what effects NKG2D stimulation has in mouse CD8
+
 T cells in the absence of 
TCR stimulation. To do this, I conducted microarray analysis of the mRNA from OT-1 CTL 
stimulated with beads coated with ICAM-1 and Rae-1ε, or ICAM-1 and Fc control. The purpose 
of ICAM-1 to these beads was to promote cell-bead contact. A Rae-1ε-Fc fusion protein was 
used to so that bead bound anti-Fc antibody could be used to attach the Rae-1ε-Fc to the bead 
surface. The same isotype antibody Fc, lacking Rae-1ε fusion, was therefore used as a control. 
OT-1 CTLs were then incubated with ICAM-1+ Rae-1ε or ICAM-1+Fc control beads at a 1:1 
ratio for 5 hours. RNA was then extracted, and analyzed by the KUMC genomics core using a 
GeneChip 430 2.0. Microarray analysis identified 9 genes whose expression was down-regulated 
more than 2-fold, and 199 genes with expression down regulated greater than 1.5-fold in CTL 
stimulated with ICAM-1 + Rae-1ε vs those stimulated with ICAM-1 + Fc control. 163 genes had 
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expression up-regulated greater than 1.5-fold, with none greater than 2.0. The top up-regulated 
(Table 3) and top down regulated (Table 4) genes are reported here. 
 
Based on their described function, I chose 11 genes of interest from the microarray, and 
confirmed expression changes with RT-qPCR of mRNA from ICAM-1 + Rae-1ε activated OT-1 
CTL vs. those activated with ICAM-1 + Fc control. These genes were Notch3, Itpka, Scin, Ftsl1, 
Ptprj, Peli1, Etxbp4, Nedd4, INPP4B, TLR4, and KLF4. Of these, I found only Nedd4 and Fstl1 
to be up-regulated. I did not further pursue this project, but given our subsequent findings of the 
importance of NKG2D signaling during CD8
+
 T cell differentiation, analysis of CD8
+
 T cell 







NOD mice were purchased from Jackson Laboratory. Klrk1
-/-
 mice on the C57BL/6 background 
have been previously described (Zafirova, Mandaric et al. 2009). The Klrk1
-/- 
allele was moved 
from the C57BL/6 to the NOD genetic background using the speed congenics service of the 
Washington University School of Medicine to generate Klrk1
-/-
 NOD mice. By SNP analysis 
(performed by DartMouse), these mice are 98% NOD, with the only observed genomic region 
containing a continuous interval of non-NOD-like SNPs found at the site of the expected site of 
the Klrk1 knockout allele. Experiments were performed with Klrk1
+/+
 (wild type) and Klrk1
-/-
 
NOD littermates from Klrk1
+/-
 NOD interbreeding. Mice were housed under specific pathogen 
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free (SPF) conditions in the Washington University School of Medicine or University of Kansas 
Medical Center animal facilities in accordance with institutional guidelines.  
 
Antibodies 
Unconjugated anti-CD28 (Clone 37.51), anti-CD3 (Clone 2C11), anti-mCD8-APC, anti-mCD4-
BV786, anti-CD3-PE-Cy7, anti-mCD107 (LAMP1)-PE, anti-DX5-FITC and anti-mCD45 were 
purchased from BD Biosciences. Anti-H60-PE, anti-mNKG2D-PE, rat IgG2a-PE and rat IgG2b-
PE were purchased from R&D Systems.  
 
In vitro CTL generation 
All cells were grown in IMDM (Cellgro) supplemented with 10% defined FBS (HyClone), 
penicillin-streptomycin-glutamine (Gibco) and β-mercaptoethanol (Sigma-Aldrich).  For 
activation of total splenocytes, spleens were harvested from 6-8 week-old SPF housed NOD 
mice, passed through a 40μm cell strainer and plated in a 6-well dish at 1.5 X 10
7 
cells/well in 3 
mL media and 1μg/mL of plate-bound anti-CD3 (2C11). For purified CD8
+
 T cells, cells were 
harvested from spleens and lymph nodes of 6-8 week-old NOD mice, and enriched by negative 
selection using magnetic beads (BD Biosciences) according to the manufacturer’s protocol. 
CD8
+
 T cells were then plated at 3-5 X 10
6
 cells/well in a 6-well dish with 1μg/mL plate-bound 
anti-C32C11) and soluble anti-CD28 (37.51). The cells were allowed to expand for 5 days and 






In vitro cytokine analysis 
CTL were harvested and plated at 1 X 10
5
 cells/well in 100 μL of fresh media in 96-well plates 
pre-coated with anti-CD3 (2C11) at the stated concentrations. Cells were incubated at 37° C for 
20 hours. Supernatant was then collected and cytokines were analyzed using the Mouse 
Inflammation Cytometric Bead Array kit (BD Biosciences) and an LSR II (BD Biosciences). 
Data were quantified using FCAP array software (BD Biosciences).   
 
In vivo cytokine analysis 
Total CD8
+
 T cells were purified from spleens and lymph nodes of 6-8 week old Klrk1
-/-
 or wild 
type NOD mice by negative selection using magnetic beads (BD Biosciences) according to the 
manufacturer’s protocol. Isolated Klrk1
-/-
 and wild type CD8
+
 T cells were then labeled with 
eFluor 670 (eBioscience) and CFSE (Thermo Scientific), respectively. The labeled cells were 
then mixed 1:1 and adoptively transferred via retro orbital injection into 6-8 week old wild type 
NOD recipient mice (Figure S2). Total splenocytes were harvested after 7 days, incubated for 4-
6 hours in complete media with GolgiPlug protein transport inhibitor (BD Biosciences), followed 
by fixation and permeablization using BD Cytofix/Cytoperm (BD Biosciences) according to 
manufacture directions. Cells were then stained overnight at 4ᵒ C with anti-mouse TNFα (BD 
Pharmingen), anti-mouse IFNγ (BD Pharmingen), and anti-mouse CD8 (BioLegend), and 
analyzed by flow cytometry. Transferred CD8
+
 T cells were analyzed by gating on live 
lymphocytes based on forward and side scatter, CD8
+ 










Lamp-1 granule release analysis 
CTL were plated at 1 X 10
5
 in 100 μL fresh media in 96-well plates pre-coated with anti-
CD32C11) at the stated concentrations. Before plating, PE- conjugated anti-CD107a was 
added to the cells at 4uL/mL. Cells were incubated at 37° C for 3 hours before being washed, 
fixed in 2% paraformaldehyde, and assessed for LAMP1 staining by flow cytometry.    
 
Antibiotic treatment of mice 
A solution of 0.5 g/L Vancomycin (Sigma-Aldrich), 1 g/L Neomycin (Sigma-Aldrich), 1 g/L 
Ampicillin (Sigma-Aldrich), and 1 g/L Metronidazole (Sigma-Aldrich) was made in grape 
KoolAid. This solution was mixed with Dietgel Boost (ClearH2O) and crushed food pellets.  
Klrk1
-/-
 and wild type NOD littermates were exclusively fed this antibiotic mixture beginning at 
weaning until euthanasia. Sequencing of the 16S rRNA genes present in feces confirmed that the 
Firmicutes and Bacteroidetes populations, the two predominant bacteria phyla present in the 
intestine, were reduced 94-99% within 4 weeks of antibiotic treatment. 
 
Diabetes determination 
In all experiments age of diabetes development was defined as the age at which the first of two 
consecutive blood glucose measurements >250 mg/dl was obtained.  
 
Statistical analysis 
Data were analyzed using a two-tailed unpaired Mann-Whitney test, one-tailed Wilcoxon test, or 




Creation of ICAM-1 + Rae1ε coated beads 
MACS anti-biotin beads (Miltenyi Biotec) were loaded with biotinylated anti-Fc antibody for at 
least 2 hrs at 4°C. After washing, beads were then incubated with a 1:1 mixture of ICAM-1-Fc 
and Rae-1ε-Fc, or a 1:1 mixture of ICAM-1-Fc and IgG1-Fc as an isotype control. Beads were 
then incubated overnight at 4°C, and washed.  
 
Microarray 
OT-1 CTL were plated in a 6-well dish at 6x10
6
 cells/well. ICAM-1-Fc + Rae-1ε-Fc or ICAM-1-
Fc + IgG1-Fc coated beads were added at a ratio of 1:1 (6x10
6
 beads/well) and allowed to 
incubate at 37°C for 5 hours. Following incubation, RNA was extracted using Trizol reagent 
according to protocol. Purified RNA was diluted to 250ug/uL and submitted to the University of 
Kansas Medical Center Genomics Core for microarray analysis using a GeneChip type: 430 2.0. 
 
Flow cytometry 
Spleens and thymi were dissociated by pressing through a 40um cell strainer in isolation buffer 
containing PBS, 2% fetal calf serum, and 2mM EDTA. Pancreata were chopped into small 
sections, digested with 1mg/ml collagenase IV (Life Technologies) in IMDM for 10 minutes at 
37 degrees with shaking, and a single cell suspension generated by pressing through a 40um cell 
strainer. The cells were then washed at least 5 times, followed by antibody staining at 4°C for at 
least 15 minutes. After staining, cells were washed and analyzed. Cultured cells were washed 





NOD diabetes transfer 
Male and female mice were used, with all transfers containing male cells going only into male 
NOD.Scid recipients. Spleens and lymph nodes from non-diabetic 6-12 week old NOD mice 
were harvested and dissociated by passing through a 40um cell strainer into isolation buffer 
containing PBS, 2% fetal calf serum, and 2mM EDTA. CD8
+
 T cells were then enriched by 
negative selection using magnetic bead separation (BD Biosciences Cat. No. 558471) according 
to the manufacturer’s instructions. CD8
+
 T cells were then stained with anti-mCD3-PE-Cy7, 

















 (Tcm) populations were 
separated by fluorescence activated cell sorting by the University of Kansas Medical Center 
Flow Core using an AriaIIIu (BD Biosciences). Separately, splenocytes from non-diabetic 6-12 
week old mice were depleted of CD8
+
 T cells by positive selection using anti-mCD8-PE (BD 





Tcm, or a mixture of 2.5X10
6 
 Teff + em and 2.5X10
6 





 T cell-depleted NOD splenocytes and adoptively transferred into 2-6 month old 
NOD.SCID mice by retro-orbital injection.  
 
In vitro cell culture 
All cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 
0.1U/mL penicillin, 0.1U/mL streptomycin, 0.29ug/mL L-glutamine, 5.5uM 2-mercaptoethanol, 
and 10% fetal calf serum.  Cells were grown at 37° C at 5% CO2.  
 
In vitro activation of mouse CD8
+





 T cells were isolated from the spleens and lymph nodes of 6-8 week-old NOD mice by 
negative selection using magnetic bead separation (BD Biosciences Cat. No. 558471) according 
to the manufacturer’s instructions. Separately, splenocytes from ubiquitous RAE1ε mice or 
control C57BL/6 mice were dissociated by passing through a 40um cell strainer and irradiated 




 T cells were then plated at a 1:4 ratio with 
either irradiated C57BL/6 RAE-1ε or C57BL/6 control splenocytes (3X10
6
anti-mCD3 (clone 2C11) in a 24 well plate.  
 
In vitro activation of B6 OT-1 CD8
+
 T cells 
Spleens were harvested from 6-12 week old SPF housed B6 OT-1 mice, passed through a 40μm 
cell strainer and plated in a 6-well dish at 1.5 X 10
7 
cells/well in 3 mL media. 1uL of 2uM OVA 
peptide was then added to each well. Cells were allowed to grow and split as needed for 5 days. 
On day 5, cells were harvested and, and live cells were separated using Ficoll Paque gradient 
according to protocol. 
 
In vitro activation of human CD8
+
 T cells 
Naïve or total CD8
+
 T cells were isolated from human peripheral blood mononuclear cells 
(PBMCs) by negative selection using the Human Naïve CD8 T Cell enrichment Set (BD 
Biosciences) and Human CD8 T Lymphocyte Enrichment Set (BD Biosciences), respectively, 
according to manufacturer’s instructions. 24 well plates were incubated with 3μg/mL anti-hCD3 
(clone: OKT3) and anti-hCD28 (clone: 9.3), along with 20μg/mL anti-hNKG2D (clone: 149810), 
or isotype control in PBS overnight at 4 degrees. The plates were washed with PBS and then the 
CD8+ T cells were added to the plate (10
6
 cells/well).  After 3 days, cells were split 1:2 and 
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-hNKG2D. After 5 days of culture, the 









Future Directions, and Conclusions 
 
Going forward there are still many avenues of investigation stemming from the findings 




 T cells 
Our data suggest that NKG2D signaling reduces the Teff+em : Tcm ratio, but also causes expansion 
of a regulatory subset of CD8
+
 T cells within the Tcm compartment. Several different populations 
of regulatory CD8
+
 T cells are known to express a Tcm phenotype (Yu, Ma et al. 2018). Here, we 






 T cells in mice, and 
CXCR3 expressing Tcm CD8
+
 T cells in humans, with preliminary results showing an increase in 
these populations with in vitro NKG2D stimulation. However, more work needs to be done to 
determine if NKG2D signaling in CD8
+
 T cells increases this regulatory population in vivo. In 
addition, more in depth characterization of the Tcm population will need to be done to identify 
other known CD8
+
 Tregs, and assess the effects of NKG2D signaling on their generation and 
















 T cells (Tang, Maricic 
et al. 2006). This same work would also assess whether NKG2D signaling is selectively driving 
expansion of a regulatory CD8
+
 T cell population within the memory compartment, or if 
regulatory CD8
+
 T cells are being expanded as a result of the increased CD8
+







NKG2D signaling and T cell metabolism 
Metabolic changes are known to drive differentiation into effector vs memory T cells, with a 
more glycolytic program favoring Teff and Tem generation, and increased oxidative 
phosphorylation (OXPHOS) and fatty acid metabolism favoring Tcm cells (Buck, Sowell et al. 
2017). In our own in vitro experiments, we have repeatedly observed increase media 
acidification in NKG2D deficient CD8
+
 T cells compared to wild type counterparts, and 
decreased relative media acidification in with NKG2D stimulation using plate bound anti-
NKG2D antibody. While these observations are somewhat anecdotal, and based on color change 
of media pH indicator, they were consistent with mouse and human CD8
+
 T cells and point to a 
change in metabolic profile with NKG2D signaling. Given our findings that NKG2D signaling in 
CD8
+
 T cells decreased the Teff + em : Tcm ratio, and the known metabolic differences between 
these two populations (Buck, Sowell et al. 2017), it is logical that we might see decreased 
acidification with NKG2D signaling. Conversely, NKG2D signaling may contribute to metabolic 
changes that in turn drive CD8
+
 Tcm generation. Indeed, NKG2D has been shown to activate 
mTOR signaling at levels that may favor differentiation of memory CD8
+
 T cells (McQueen, 
Trace et al. 2016), and mTOR is known to be a key regulator of cellular metabolism (Saxton and 
Sabatini 2017) and mitochondrial dynamics (Morita, Prudent et al. 2017). In T cells, mTOR is 
further known to direct differentiation and cell fate through metabolic regulation (Salmond 
2018). A study by Buck et al. demonstrates how a metabolic shift towards increased OXPHOS 
resulting from mitochondrial fusion is capable of driving memory T cell formation, even in the 
presence of otherwise activating signals favoring effector T cell development (Buck, O'Sullivan 
et al. 2016). This finding suggests that altered metabolism favoring increased OXPHOS may not 
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result from memory T cell differentiation, but may instead drive it. Future work may therefore 
focus on elucidating how NKG2D signaling contributes to a shift in CD8
+
 T cell metabolism 
favoring Tcm cell generation.  
 
TCR signaling and memory generation 
Work out of the lab of Dr. Pere Santamaria has shown that CD8
+
 T cells with low avidity TCR 
against autoantigen differentiate into a regulatory CD8
+
 T cell population which is protective in 
NOD mice (Tsai, Shameli et al. 2010, Shameli, Clemente-Casares et al. 2011). Here NKG2D 
could potentially play a role in increasing generation of memory phenotype regulatory CD8
+
 T 
cells either by enhancing survival of these low avidity cells, or by providing differentiating 
signals in the absence of signaling by a higher avidity TCR.  
 
Interesting Parallels with P2X7  
P2X7, encoded by P2Rx7, is a ligand gated ion channel which recognizes extracellular ATP. It is 
expressed on many immune cells, and allows passage of cations in response to elevated levels of 
extracellular ATP. In response to prolonged exposure to high concentrations of extracellular 
ATP P2X7 can trigger apoptosis by the formation of large non-specific membrane pores (Savio, 
de Andrade Mello et al. 2018). The P2RX7 gene has been proposed as a T1D susceptibility gene 
in NOD mice. Interestingly, a polymorphism in the P2X7 receptor has been described in 
C57BL/6 and DBA/2 mice, which greatly decreases the sensitivity of the receptor to ATP 
(Adriouch, Dox et al. 2002). This polymorphism was not observed in Balb/c (Adriouch, Dox et 
al. 2002, Syberg, Schwarz et al. 2012), 129, or NOD mice (Syberg, Schwarz et al. 2012). P2X7 
signaling has been well established in driving an inflammatory response by stimulating the 
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production of pro-inflammatory cytokines by immune cells, in particular acting as a major driver 
or NLRP3 inflammasome activation and IL-1β release (Di Virgilio, Dal Ben et al. 2017). 
However, P2X7 has also been shown to have anti-inflammatory effects, with P2X7 activation 
being found to control inflammatory Th1 and Th17 cells and suppress T cell induced colitis in 
mice (Hashimoto-Hill, Friesen et al. 2017). In experimental autoimmune encephalomyelitis, 
genetic knockout of P2X7 was also found to worsen disease (Chen and Brosnan 2006). P2X7 has 
been shown to be protective in a mouse model of rheumatoid arthritis as well by inducing 
apoptosis in Payers Patch T follicular helper cells (Felix, Teng et al. 2019). While suggested to 
be a T1D susceptibility locus, the role of P2X7 in autoimmune diabetes remains unclear. A study 
by Chen et al. found that P2X7 deficiency alone did not affect NOD diabetes incidence, but lead 
to decreased in disease incidence in P2X7 and CD38 double knockout animals (Chen, 
Scheuplein et al. 2011). In this study, the authors point out the pleiotropic effects of P2X7 on 
inflammation, and suggest that P2X7 may be acting with multiple pro-diabetic and anti-diabetic 
effects on different cells making the individual effects of P2X7 difficult to distinguish (Chen, 
Scheuplein et al. 2011).  
 It is likely that NKG2D signaling does not play a role in the regulation of immune cells 
through P2X7 induced apoptosis. However, P2X7 has recently been found to play an important 
role in the generation and maintenance of CD8
+
 Tcm cells (Borges da Silva, Beura et al. 2018). In 
this report the authors show that P2X7 signaling in response to extracellular ATP both increases 
intracellular calcium and likely participates in a feed forward loop enhancing release of ATP by 
Pannexin 1. Further, they show that the resulting increase in intracellular calcium and decrease in 
intracellular ATP levels activate AMPK promoting enhanced mitochondrial function and 
biogenesis (Borges da Silva, Beura et al. 2018). The authors suggest that this increased 
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mitochondrial mass and corresponding increase in OXPHOS capacity leads to the increased 
survival of CD8
+
 Tcm cell compartment (Borges da Silva, Beura et al. 2018). Indeed, increased 
mitochondrial biogenesis, and increased capacity for OXPHOS are known to be important for the 
formation and survival of memory T cells (Buck, Sowell et al. 2017). In their 2018 study, Borges 
Da Silva et al. did not extensively investigate the source of extracellular ATP, but did show that 
Pannexin 1 was likely the key mediator of ATP release, and posit that P2X7 activation of 
Pannexin 1 could be responsible for sustained ATP release and continued signaling (Borges da 
Silva, Beura et al. 2018). Interestingly, P2X7 is not the only activator of Pannexin 1, and it has 
been shown that Pannexin 1 can be directly activated by caspase 3 mediated cleavage of a C 
terminal inhibitory domain (Sandilos, Chiu et al. 2012). In T cells, caspases 3 and 7 have been 
shown to be activated, without initiation of apoptotic pathways, by chronic NKG2D signaling 
(Hanaoka, Jabri et al. 2010). Therefore, it is feasible to think that sustained NKG2D signaling in 
CD8
+
 T cells by NKG2D ligand expressed by immune cells enhances or initiates Pannexin 1-
ATP-P2X7 driven signaling leading to increased CD8
+
 Tcm cell populations.  
 
Conclusions 
The beginning of this dissertation laid out the complex challenges faced by the immune system 
in identifying and defeating potential immunological threats while simultaneously regulating a 
response to minimize damage to healthy tissues. In autoimmune diabetes, this regulation has 
failed. However, the very complexity that allows for diverse and effective immunity also 
complicates our ability to understand which combinations of factors have gone awry leading to 
autoimmunity. Strong evidence supports the involvement of the immune receptor NKG2D in the 
development of autoimmune diabetes in both mice and humans. Indeed, it seems logical that a 
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receptor which canonically functions to identify and direct killing of ligand expressing targets 
cells may inadvertently be acting against healthy insulin producing β-islet cells in the pancreas. 
An initial investigation seemed to support this role for NKG2D in NOD diabetes development. 
However subsequent conflicting reports cast doubt on the role of NKG2D-mediated killing of 
pancreatic cells as a mechanism of autoimmunity, and suggest that NKG2D signaling plays a 
more complex role shaping an immune response.  
 
The findings presented in this dissertation support the idea that NKG2D signaling in CD8
+
 T 
cells plays a protective role in the development of autoimmune diabetes. We first demonstrate 
that NKG2D ligands are expressed by healthy immune cells, and that NKG2D-NKG2D ligand 
interactions between CD8
+
 T cells during T cell differentiation reduced their later cytokine 
response. This effect correlated with a reduction in diabetes both between NKG2D sufficient vs. 
NKG2D deficient mice which were treated with microbiota depleting antibiotics, as well as NOD 
RIP-Rae1ε mice, which have increased NKG2D signaling within the pancreas, compared to 
control. It should however be noted that a major challenge yet remaining is to demonstrate that 
NKG2D signaling on CD8
+
 T cells is responsible for the observed protective effect of NKG2D 
in antibiotic treated animals. Finding that the population of CD8
+
 T cells in the spleen and 
pancreas of NOD RIP-Rae1ε mice contained a decreased ratio of Teff+em to Tcm cells lead to the 
finding that NKG2D stimulation increased Tcm generation in both human and mouse CD8
+
 T 
cells in vitro, and in both cases reduced the ratio of CD8
+
 Teff+em to Tcm cells. My finding that 
NKG2D stimulation in vitro also increased PD-1 expression by mouse CD8
+
 T cells, and 
increased generation of a human CD8
+
 Treg phenotype population, further suggests an immune 
regulatory role for NKG2D signaling between CD8
+




In conclusion, I have described a novel role for NKG2D signaling on CD8
+
 T cells, whereby 
NKG2D interacts with ligand expressed by healthy immune cells, and plays a regulatory role 
shaping the immune response. While there is still significant work to be done to further 
characterize this mechanism, the protective role we find for NKG2D in autoimmune diabetes 
may explain the conflicting reports regarding the role of NKG2D in the disease, when taken in 
conjunction with evidence for a separate detrimental effect of NKG2D signaling. Finally, I feel 
that these findings represent a general mechanism for NKG2D acting in directing CD8
+
 T cell 
development with broader implication in other autoimmune conditions, anti-tumor responses, 
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